[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Remel Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":235},{"warningLetters":4,"total":234},[5,30,52,72,91,112,133,150,170,191,214],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},656,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fremedy-meds-716830-09092025\">Remedy Meds\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Remedy Meds\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>480 Morris Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Summit\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07901\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@remedymeds.com\"> support@remedymeds.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Remedy Meds:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fremedymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Semaglutide (Compounded) Same active ingredient as Ozempic and Wegovy”\u003C\u002Fli>\u003Cli>“Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRemedy Meds\n\n480 Morris Ave\n\nSummit, NJ 07901\n\nUnited States\n\nsupport@remedymeds.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nRemedy Meds:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fremedymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.1 As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Semaglutide (Compounded) Same active ingredient as Ozempic and Wegovy”\n“Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_____________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Remedy Meds","remedy-meds-716830-09092025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fremedy-meds-716830-09092025","2026-10-26T08:09:48.555528+00:00","Warning Letter","Issued","2025-09-16","716830","Drugs","2026-08-19T16:24:11.695+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-09",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":47,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},2063,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2023-06-06T13:20:00Z\">06\u002F06\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-11T04:00:00Z\">05\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fremedyrepack-inc-649198-05112023\">RemedyRepack, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Mark Zilner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>RemedyRepack, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>625 Kolter Drive, Suite 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indiana\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>15701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 649198\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMay 11, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Zilner:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, RemedyRepack, Inc., FEI 3005841768, at 625 Kolter Drive, Suite 4, Indiana, PA, from November 7 to November 10, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 21, 2022 response to our Form FDA 483 in detail, and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your cleaning processes for drug manufacturing equipment, including those used for blister card and liquid repacking operations, were inadequate. For example, your quality control checks failed to identify contaminated surfaces of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> blister card packaging equipment. You also noted multiple occurrences of visibly contaminated tablets and capsules. Furthermore, you lacked chemical testing to confirm your cleaning procedures sufficiently removed product residues and cleaning agents from your equipment.\u003C\u002Fp>\n\n\u003Cp>In addition, we note you lacked adequate studies to support your clean hold times.\u003C\u002Fp>\n\n\u003Cp>In your response you commit to updating your current cleaning validation procedures and performing new cleaning validations. You also state you will re-clean machines that have been stored more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to use.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You fail to provide scientific evidence demonstrating your interim cleaning procedure will sufficiently remove potential contaminants, such as product residues, cleaning and sanitizing agents, and objectionable organisms. You also did not provide your cleaning validation protocol indicating the relevant sources of risk, predetermined acceptance criteria, acceptable amount of time for storing dirty equipment, and other considerations relevant to your equipment cleaning program. Furthermore, you fail to assess the impact of your inadequate cleaning processes on product that is currently on the market and within expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fp>\n\n\u003Cp>• A corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; &nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o maximum hold times before cleaning each piece of equipment\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment addressing the hazards posed by distributing drug products manufactured using shared equipment that may have been improperly cleaned. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your investigations lacked sufficient root cause determinations, CAPA, and assessment of all potentially affected batches. For example, you identified multiple deviations for numerous broken tablets caused by your packaging equipment between October 20, 2021, and November 8, 2021. You treated these similar deviations as individual occurrences and did not address this adverse pattern. Your investigations, each of which was signed by quality assurance staff, determined no further action was necessary, and did not provide any explanation for this conclusion. In one instance, you stated these tablets “are tiny and do not run well” on your repackaging equipment, though you lacked adequate root cause determination and did not implement any CAPA.\u003C\u002Fp>\n\n\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you state “relevant” employees will be retrained in conducting proper assessments and investigations, and new employees will receive thorough training to ensure they fully understand the requirements.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. It fails to provide a comprehensive investigation into the broken tablet deviations, and you do not extend your investigations to other batches to determine the full scope and product impact of the deviations. Furthermore, you do not implement CAPA plans to prevent these issues from reoccurring. In addition, your response does not specify whether the “relevant” employees to receive investigation training will include manufacturing operators, supervisors, management, quality personnel, or other staff.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to provide adequate data to demonstrate you validated your drug packaging processes to ensure consistent product quality. For example, you packaged and distributed various drug products which lacked product-specific packaging validation protocols with pre-approved acceptance criteria.\u003Cbr>\n\u003Cbr>\nYou also experienced numerous deviations for tablets that broke during packaging, and your firm was aware that small tablets do not run well on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging machine.\u003C\u002Fp>\n\n\u003Cp>You also failed to adequately qualify your drug packaging equipment. Though you provided a procedure titled, “Validation Protocol,” you lacked adequate equipment-specific protocols to reveal the limits of capability of the equipment you use to package drug products.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you are enhancing your validation and qualification programs to include protocols, acceptance criteria, additional testing, and a final summary of your findings.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You fail to include or otherwise address your risk assessment for any marketed drug products manufactured and distributed with unvalidated packaging processes. You also do not provide an assessment of the product quality impact on distributed drug products you packaged on equipment that lacks adequate qualification studies.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\u003C\u002Fp>\n\n\u003Cp>• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fp>\n\n\u003Cp>• Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control.\u003C\u002Fp>\n\n\u003Cp>• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your facility design is inadequate to prevent cross-contamination. You repackage non-penicillin beta-lactam drugs in the same facility as non-beta-lactam drugs, rather than in separate dedicated facilities. Complete and comprehensive separation of beta-lactam repackaging operations is essential due to the severe patient risk posed by cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Contamination of non-beta-lactam drugs with beta-lactam drugs presents great risk to patient safety, including potential anaphylaxis and death. No safe level of beta-lactam contamination has been determined to be a tolerable risk. Severe allergenic responses can occur in susceptible patients exposed to extremely low levels of beta-lactams.\u003C\u002Fp>\n\n\u003Cp>In your correspondence of March 3, 2023, you state you have “never experienced a breach in containment of beta-lactams.” However, you also explain you have not performed environmental sampling for beta-lactam contamination. In your reasoning for this decision, you explain most beta-lactam products you process are in capsule form, in small quantities, and repackaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> in an “isolated” environment with HEPA filtration. You also include rudimentary floor plans and photos of your production areas, which indicate that your non-penicillin beta-lactam operations are not conducted in a separate building or comprehensively sealed-off facility.\u003C\u002Fp>\n\n\u003Cp>Your facilities and practices are inadequate. You state you have not had a breach in beta-lactam containment, but you lack data to support this conclusion. You also have not initiated environmental monitoring or assessed the product quality impact of potential breaches on distributed product. You also fail to implement a design at your site that ensures complete and comprehensive physical separation of your non-penicillin beta-lactam operations.\u003C\u002Fp>\n\n\u003Cp>Notably, you use a separate building on your campus to repackage penicillins. Similarly, it is essential that your firm use separate facilities for the processing of non-penicillin beta-lactam drugs.\u003C\u002Fp>\n\n\u003Cp>Separation of non-penicillin beta-lactam drugs nearly always necessitates use of a building dedicated to only those drugs. In very limited instances, two facilities could potentially be housed in the same building. However, in such rare cases, a continuous solid impervious wall separates two comprehensively distinct facilities which are fully sealed-off from each other. These two separate physical facilities exist within an external building structure, but with separate entries, exits, facility infrastructure, air handling, personnel, and which by design completely preclude any potential for incidental air, personnel, materials, or other interactions. Under the limited cases in which this design concept could be considered, a rigorous risk assessment would demonstrate that the design provides as much protection against cross-contamination as is achieved by manufacturing in a separate building.\u003C\u002Fp>\n\n\u003Cp>Because of the extremely low threshold dose at which an allergic response could occur, beta-lactam facilities need to be completely and comprehensively separated from non-beta-lactam facilities. For more information, see FDA’s guidance document, Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F79971\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your plan to fully dedicate your facility to beta-lactams or cease any beta-lactam production in the building. Regarding the latter, if you intend to attempt decontamination so that your facility can resume solely non-beta lactam production, facility decontamination would be necessary and you will need to develop a comprehensive decontamination plan for the facility. Your plan should include all equipment and facility parts that will be removed. The design and remediation plan should be premised on the knowledge that it is profoundly difficult to completely decontaminate a facility of beta-lactam residues.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment by a qualified third party regarding future measures to prevent risk of beta-lactam cross-contamination. The assessment should identify any inadequacies in assuring complete physical facility separation of beta-lactam and non-beta-lactam production, as well as controls to prevent personnel use of common areas. Describe the extensive remediations to design and controls that support dedicated facilities with complete and comprehensive separation (i.e., isolated and sealed off). Details regarding the remediated site should include but not be limited to air intake and exhaust, vacuum systems, HVAC filter locations, entry points, egress points, people\u002Fmaterial\u002Fequipment flow, personnel gowning, physical containment devices for packaging equipment, material storage, common area separation, decontamination practices, monitoring containment, and testing.\u003C\u002Fp>\n\n\u003Cp>• Provide timelines for the independent assessment and how you intend to evaluate the effectiveness of your CAPA.\u003C\u002Fp>\n\n\u003Cp>• Your immediate plan to perform environmental sampling of your facility for beta-lactam cross-contamination, including frequency and sampling locations using robust and validated methodologies. In addition, provide any testing performed to date. Assure your method for detecting beta-lactams provides appropriate sensitivity to detect very low levels of contamination; see FDA’s published analytical method which has a LOD of 0.2 ppb at https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fpubmed\u002F29766324. If such testing reveals recovery of beta-lactams, take rapid corrective actions, such as notifying customers, and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>• A list of all decontaminant solutions used in your facility, including validation data to support that the decontaminant solutions can break the beta-lactam ring of the beta-lactam drug products repackaged.\u003C\u002Fp>\n\n\u003Cp>• A program for future monitoring of beta-lactam residue throughout the site.\u003C\u002Fp>\n\n\u003Cp>• Floor plans for each building and facility where repackaging operations occur, clearly illustrating the flow of materials and personnel, as well as areas used for cleaning, air locks, or other purposes relevant to drug production. Also describe which specific product types can be repackaged, sampled, or otherwise manipulated in each of the buildings and facilities, as well as which product types are not permitted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 649198 and include FEI: 3005841768.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer Samina Khan at samina.khan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Mark Zilner\n\nRecipient Title\n\nPresident\n\nRemedyRepack, Inc.\n\n625 Kolter Drive, Suite 4\n\nIndiana, PA 15701\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER 649198\n\nMay 11, 2023\n\nDear Mr. Zilner:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, RemedyRepack, Inc., FEI 3005841768, at 625 Kolter Drive, Suite 4, Indiana, PA, from November 7 to November 10, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your November 21, 2022 response to our Form FDA 483 in detail, and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour cleaning processes for drug manufacturing equipment, including those used for blister card and liquid repacking operations, were inadequate. For example, your quality control checks failed to identify contaminated surfaces of your (b)(4) blister card packaging equipment. You also noted multiple occurrences of visibly contaminated tablets and capsules. Furthermore, you lacked chemical testing to confirm your cleaning procedures sufficiently removed product residues and cleaning agents from your equipment.\n\nIn addition, we note you lacked adequate studies to support your clean hold times.\n\nIn your response you commit to updating your current cleaning validation procedures and performing new cleaning validations. You also state you will re-clean machines that have been stored more than (b)(4) prior to use.\n\nYour response is inadequate. You fail to provide scientific evidence demonstrating your interim cleaning procedure will sufficiently remove potential contaminants, such as product residues, cleaning and sanitizing agents, and objectionable organisms. You also did not provide your cleaning validation protocol indicating the relevant sources of risk, predetermined acceptance criteria, acceptable amount of time for storing dirty equipment, and other considerations relevant to your equipment cleaning program. Furthermore, you fail to assess the impact of your inadequate cleaning processes on product that is currently on the market and within expiry.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\n• A corrective action and preventive action (CAPA) plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning each piece of equipment\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n• A detailed risk assessment addressing the hazards posed by distributing drug products manufactured using shared equipment that may have been improperly cleaned. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour investigations lacked sufficient root cause determinations, CAPA, and assessment of all potentially affected batches. For example, you identified multiple deviations for numerous broken tablets caused by your packaging equipment between October 20, 2021, and November 8, 2021. You treated these similar deviations as individual occurrences and did not address this adverse pattern. Your investigations, each of which was signed by quality assurance staff, determined no further action was necessary, and did not provide any explanation for this conclusion. In one instance, you stated these tablets “are tiny and do not run well” on your repackaging equipment, though you lacked adequate root cause determination and did not implement any CAPA.\n\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\n\nIn your response, you state “relevant” employees will be retrained in conducting proper assessments and investigations, and new employees will receive thorough training to ensure they fully understand the requirements.\n\nYour response is inadequate. It fails to provide a comprehensive investigation into the broken tablet deviations, and you do not extend your investigations to other batches to determine the full scope and product impact of the deviations. Furthermore, you do not implement CAPA plans to prevent these issues from reoccurring. In addition, your response does not specify whether the “relevant” employees to receive investigation training will include manufacturing operators, supervisors, management, quality personnel, or other staff.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to provide adequate data to demonstrate you validated your drug packaging processes to ensure consistent product quality. For example, you packaged and distributed various drug products which lacked product-specific packaging validation protocols with pre-approved acceptance criteria.\n\nYou also experienced numerous deviations for tablets that broke during packaging, and your firm was aware that small tablets do not run well on your (b)(4) packaging machine.\n\nYou also failed to adequately qualify your drug packaging equipment. Though you provided a procedure titled, “Validation Protocol,” you lacked adequate equipment-specific protocols to reveal the limits of capability of the equipment you use to package drug products.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn your response, you state you are enhancing your validation and qualification programs to include protocols, acceptance criteria, additional testing, and a final summary of your findings.\n\nYour response is inadequate. You fail to include or otherwise address your risk assessment for any marketed drug products manufactured and distributed with unvalidated packaging processes. You also do not provide an assessment of the product quality impact on distributed drug products you packaged on equipment that lacks adequate qualification studies.\n\nIn response to this letter, provide:\n\n• A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\n\n• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n• Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control.\n\n• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\n4. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).\n\nYour facility design is inadequate to prevent cross-contamination. You repackage non-penicillin beta-lactam drugs in the same facility as non-beta-lactam drugs, rather than in separate dedicated facilities. Complete and comprehensive separation of beta-lactam repackaging operations is essential due to the severe patient risk posed by cross-contamination.\n\nContamination of non-beta-lactam drugs with beta-lactam drugs presents great risk to patient safety, including potential anaphylaxis and death. No safe level of beta-lactam contamination has been determined to be a tolerable risk. Severe allergenic responses can occur in susceptible patients exposed to extremely low levels of beta-lactams.\n\nIn your correspondence of March 3, 2023, you state you have “never experienced a breach in containment of beta-lactams.” However, you also explain you have not performed environmental sampling for beta-lactam contamination. In your reasoning for this decision, you explain most beta-lactam products you process are in capsule form, in small quantities, and repackaged (b)(4) in an “isolated” environment with HEPA filtration. You also include rudimentary floor plans and photos of your production areas, which indicate that your non-penicillin beta-lactam operations are not conducted in a separate building or comprehensively sealed-off facility.\n\nYour facilities and practices are inadequate. You state you have not had a breach in beta-lactam containment, but you lack data to support this conclusion. You also have not initiated environmental monitoring or assessed the product quality impact of potential breaches on distributed product. You also fail to implement a design at your site that ensures complete and comprehensive physical separation of your non-penicillin beta-lactam operations.\n\nNotably, you use a separate building on your campus to repackage penicillins. Similarly, it is essential that your firm use separate facilities for the processing of non-penicillin beta-lactam drugs.\n\nSeparation of non-penicillin beta-lactam drugs nearly always necessitates use of a building dedicated to only those drugs. In very limited instances, two facilities could potentially be housed in the same building. However, in such rare cases, a continuous solid impervious wall separates two comprehensively distinct facilities which are fully sealed-off from each other. These two separate physical facilities exist within an external building structure, but with separate entries, exits, facility infrastructure, air handling, personnel, and which by design completely preclude any potential for incidental air, personnel, materials, or other interactions. Under the limited cases in which this design concept could be considered, a rigorous risk assessment would demonstrate that the design provides as much protection against cross-contamination as is achieved by manufacturing in a separate building.\n\nBecause of the extremely low threshold dose at which an allergic response could occur, beta-lactam facilities need to be completely and comprehensively separated from non-beta-lactam facilities. For more information, see FDA’s guidance document, Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F79971\u002Fdownload.\n\nIn response to this letter, provide:\n\n• Your plan to fully dedicate your facility to beta-lactams or cease any beta-lactam production in the building. Regarding the latter, if you intend to attempt decontamination so that your facility can resume solely non-beta lactam production, facility decontamination would be necessary and you will need to develop a comprehensive decontamination plan for the facility. Your plan should include all equipment and facility parts that will be removed. The design and remediation plan should be premised on the knowledge that it is profoundly difficult to completely decontaminate a facility of beta-lactam residues.\n\n• A comprehensive, independent assessment by a qualified third party regarding future measures to prevent risk of beta-lactam cross-contamination. The assessment should identify any inadequacies in assuring complete physical facility separation of beta-lactam and non-beta-lactam production, as well as controls to prevent personnel use of common areas. Describe the extensive remediations to design and controls that support dedicated facilities with complete and comprehensive separation (i.e., isolated and sealed off). Details regarding the remediated site should include but not be limited to air intake and exhaust, vacuum systems, HVAC filter locations, entry points, egress points, people\u002Fmaterial\u002Fequipment flow, personnel gowning, physical containment devices for packaging equipment, material storage, common area separation, decontamination practices, monitoring containment, and testing.\n\n• Provide timelines for the independent assessment and how you intend to evaluate the effectiveness of your CAPA.\n\n• Your immediate plan to perform environmental sampling of your facility for beta-lactam cross-contamination, including frequency and sampling locations using robust and validated methodologies. In addition, provide any testing performed to date. Assure your method for detecting beta-lactams provides appropriate sensitivity to detect very low levels of contamination; see FDA’s published analytical method which has a LOD of 0.2 ppb at https:\u002F\u002Fwww.ncbi.nlm.nih.gov\u002Fpubmed\u002F29766324. If such testing reveals recovery of beta-lactams, take rapid corrective actions, such as notifying customers, and initiating recalls.\n\n• A list of all decontaminant solutions used in your facility, including validation data to support that the decontaminant solutions can break the beta-lactam ring of the beta-lactam drug products repackaged.\n\n• A program for future monitoring of beta-lactam residue throughout the site.\n\n• Floor plans for each building and facility where repackaging operations occur, clearly illustrating the flow of materials and personnel, as well as areas used for cleaning, air locks, or other purposes relevant to drug production. Also describe which specific product types can be repackaged, sampled, or otherwise manipulated in each of the buildings and facilities, as well as which product types are not permitted.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 649198 and include FEI: 3005841768.\n\nIf you have any questions, contact Compliance Officer Samina Khan at samina.khan@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations Division I\n\n___________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","RemedyRepack, Inc.","remedyrepack-inc-649198-05112023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fremedyrepack-inc-649198-05112023","2026-10-26T08:09:48.594335+00:00","2023-06-06","649198","Division of Pharmaceutical Quality Operations I","Mr. Mark Zilner","2026-08-20T01:04:09.795+00:00","VIA Electronic Mail","2023-05-11",{"id":53,"raw":54,"subject":37,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":67,"body_fetched_at":68,"delivery_method":69,"recipient_title":19,"reference_number":70,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},1102,[55,56,57,11,37,13,13,13],"\u003Ctime datetime=\"2025-01-07T14:20:00Z\">01\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-16T05:00:00Z\">12\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Findoco-remedies-limited-691594-12162024\">Indoco Remedies Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-23\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Aditi Kare Panandikar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Indoco Remedies Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Indoco House, 166, C.S.T Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kalina Santacruz (E)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mumbai\u003C\u002Fspan> \u003Cspan>400098\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-23\u003C\u002Fp>\u003Cp>December 16, 2024\u003C\u002Fp>\u003Cp>Dear Ms. Panandikar:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Indoco Remedies Limited, FEI 3005124189, at L 32 33 - 34 I D C Verna Industrial Road, Vasco Da Gama, Goa, India, from July 16 to 26, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 15, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to record and justify any deviations from required laboratory control mechanisms (21 CFR 211.160(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked adequate controls to assure the reliability of microbiological testing results. For example:\u003C\u002Fp>\u003Cp>A. Numerous non-viable dark particles were observed in \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates used for microbiological analyses in your laboratory.\u003C\u002Fp>\u003Cp>B. Non-viable dark particles were observed on filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> microbiological testing.\u003C\u002Fp>\u003Cp>C. Media plates prepared in-house did not consistently possess smooth surfaces needed to ensure maximum contact of test articles to facilitate the growth of any microbiological organisms present.\u003C\u002Fp>\u003Cp>D. Analysts did not consistently ensure filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> on media plates during microbiological testing needed to ensure maximum contact of filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> to facilitate the growth of any microbiological organisms present.\u003C\u002Fp>\u003Cp>In your response, you indicate you discontinued use of, and discarded, the implicated filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot associated with the observed particulate matter and are attempting to identify an alternate vendor. You also performed a retrospective review of \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data, and you do not identify any similar instances of air bubbles being observed during testing. You conclude any incidence of failing to ensure filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> on media plates during testing are “rare” and do not impact product quality.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not holistically assess microbiological laboratory conditions and practices and their impact on the reliability of microbiological test results. Your retrospective review protocol to identify instances of \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> during testing is insufficient as it relies on documentation of events that were not being recorded by your analysts. Additionally, the conclusion of the retrospective review stating there was no impact on product quality lacks scientific justification, in that contact between the filter \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the media is essential for the growth and identification of any microbiological organisms on the filter \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all microbiological test data for products currently in the U.S. market and within expiry as of the date of this letter to assess the impact of the observed laboratory conditions and practices on the reliability of the microbiological test data. The review should include testing performed in support of qualification and validation activities currently relied upon to support the manufacture of drug products for the U.S. market.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of equipment and test supplies are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable equipment and test supplies.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our review found deficiencies in video recordings of airflow (smoke) studies executed in the ISO 5 areas including on Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the empty vial \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the nozzle \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, the presence of excessive smoke prevented visualization of airflows. The inadequate visualization of airflow is a repeated from the 2023 inspection of your facility.\u003C\u002Fp>\u003Cp>In your response, you commit to providing additional training to personnel responsible for the execution of airflow studies and to conduct new studies.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your previous actions taken to prevent recurrence were inadequate. You do not commit to reassessing your training program or the failure of previously implemented corrective action and preventive action (CAPA) to remediate the airflow studies. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An independent assessment of the training provided to personnel responsible for the execution of airflow study protocols.\u003C\u002Fli>\u003Cli>An independent assessment of the CAPA effectiveness in response to previous adverse findings associated with your conduct of airflow studies. The assessment should include the determination of root cause(s), CAPA, and a description of how the CAPA effectiveness will be determined.\u003C\u002Fli>\u003Cli>A revised Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> airflow study protocol, completed protocol report, the airflow study videos, and an independent assessment of the aforementioned protocol, complete protocol report, and airflow study videos.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions (21 CFR 211.42(c)(10)(vi)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our review found unsuitable conditions in ISO 5 areas where aseptic processing is conducted. For example:\u003C\u002Fp>\u003Cp>A. Rough metal surfaces and an incomplete \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed on the Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> Restricted Access Barrier System (RABS) framework in the area above the stopper loading chute.\u003C\u002Fp>\u003Cp>B. \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed protruding through the interior of RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS in the area above the stopper loading chute.\u003C\u002Fp>\u003Cp>C. \u003Cstrong>(b)(4)\u003C\u002Fstrong> conduit was present with exposed wires and not properly secured to the adjoining surface in the Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> filtration area.\u003C\u002Fp>\u003Cp>You previously remediated the Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS in response to the unsuitable physical condition of Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> documented in the 2023 inspection of this facility. Your remediation activities failed to wholistically address the conditions of the Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS.\u003C\u002Fp>\u003Cp>In your response, you report Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> were inspected for additional “uneven rough surfaces,” commit to inspecting Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the future, and updating procedures to require the inspection of areas for the presence of uneven and rough surfaces. You report an inspection of Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> for areas that are difficult to clean and identified a root cause for the electrical conduit not being properly secured as “improper verification” of the conduit. You also report the conduct of “Awareness Training” of personnel in your Engineering department.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not:\u003C\u002Fp>\u003Cul>\u003Cli>Evaluate the training of personnel responsible for inspection activities.\u003C\u002Fli>\u003Cli>Perform a comprehensive assessment of all lines and equipment therein to ensure appropriate design and suitability of materials of construction and equipment.\u003C\u002Fli>\u003Cli>Comprehensively assess procedures governing equipment design to ensure appropriate user requirements are established.\u003C\u002Fli>\u003Cli>Assess the quality unit’s (QU) role in assuring the suitability of the facility and equipment therein.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In response to this letter, provide your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Explain how you will use qualified third-party consultant(s) to assist you in development, execution, and assessment of CAPA effectiveness for these activities.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into product quality defect complaints are not consistently and scientifically supported and rely on flawed analyses to reach conclusions on product quality impact. For example:\u003C\u002Fp>\u003Cp>A. Your investigation into complaints of dispensing tip (nozzle) blockage associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution USP \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution USP, \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg\u002Fml and \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg\u002FmL (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) concluded the tip blockage phenomena was due to improper storage by patients. You stated the ensuing exposure of product solutions to air resulted in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> excipient in the formulations forming a film or precipitating and blocking the dispensing tips. Your investigation is deficient for reasons including, but not limited to:\u003Cbr>1. Neither of the scientific publication sources cited in your investigation support your root cause.\u003Cbr>2. Your experimental study compared the effect of atmospheric exposure of a freshly prepared solution by your research and development group against samples of innovator product that expired approximately 2.5 years earlier.\u003C\u002Fp>\u003Cp>B. Your investigations into complaints of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products missing tips or being received empty by patients were repeatedly determined to have no impact on product quality. This conclusion conflicts with the finished product quality attributes for fill volume.\u003C\u002Fp>\u003Cp>In your response, you report your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also report the revision of your complaint handling procedure and your plan to evaluate the function of equipment used to detect missing container closure system components.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sound scientific data or other relevant information supporting your conclusion that atmospheric exposure of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in these products is solely responsible for the tip blockage complaints. You also did not adequately address empty units being received by patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A scientifically sound investigation into the tip blockage issue. The investigation should identify root cause(s), CAPA, and the mechanism(s) for determining CAPA effectiveness.\u003C\u002Fli>\u003Cli>An independent evaluation of your product quality complaint handling procedures and practices including relevant procedures and practices used by contracted third parties that perform complaint handling activities on your behalf. The independent evaluation should include identification of all deficiencies, assignment of appropriate CAPA, and the mechanism(s) for determining CAPA effectiveness.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Warning and error messages in the Empower Message Center included in your chromatography data software are not reviewed. For example, during the 20-day period between December 26, 2023, and January 15, 2024, the following error messages were registered in the Empower Message Center:\u003C\u002Fp>\u003Cp>A. Approximately 33 instances of “Injection --- cannot be altered. It belongs to a sample set which is currently being acquired”\u003C\u002Fp>\u003Cp>B. Approximately 60 instances of “User Abort”\u003C\u002Fp>\u003Cp>C. Approximately 18 instances of “Stop Flow key was pressed”\u003C\u002Fp>\u003Cp>The procedures governing chromatography analyses do not require the review of all audit trail data. Your personnel were unaware of the requirement to review the Empower Message Center data in Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong> analyses during the inspection. The error and warning messages in the Empower Message Center can be an indicator of problems with equipment and method suitability.\u003C\u002Fp>\u003Cp>In your response, you report revisions to the procedures governing chromatography analyses in Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong> to require the review of data in the Empower Message Center. You also report the conduct of a “comprehensive review” of data in the Empower Message Center in Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong> and corresponding risk assessments. You also indicate you do not review the Empower Message Center as required by your procedure governing chromatography analyses in Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your review of data in the Empower Message Center failed to identify unexpected discrepancies including approximately 32 of the 33 instances of “Injection --- cannot be altered. It belongs to a sample set which is currently being acquired” messages generated between December 26, 2023, and January 15, 2024, were associated with the same user. You also did not identify and investigate the relatively high number of “User Abort” messages generated over the same timeframe.\u003C\u002Fp>\u003Cp>In response to this letter, provide an independent, retrospective assessment of Empower Message Center data for the last three years from the initial date of inspection and a report summarizing the findings of the analysis. The analysis should include trending of pertinent data including, but not limited to, specific users, methods, and equipment.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous inspection, dated February 20 to February 28, 2023, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Indoco Remedies Ltd., L 32 33 - 34 I D C Verna Industrial Road, Vasco Da Gama, Goa, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005124189 and ATTN: Jason F. Chancey.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-23\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Aditi Kare Panandikar\n\nRecipient Title\n\nManaging Director\n\nIndoco Remedies Limited\n\nIndoco House, 166, C.S.T Road\n\nKalina Santacruz (E)\n\nMumbai 400098\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-23\nDecember 16, 2024\nDear Ms. Panandikar:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Indoco Remedies Limited, FEI 3005124189, at L 32 33 - 34 I D C Verna Industrial Road, Vasco Da Gama, Goa, India, from July 16 to 26, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 15, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to record and justify any deviations from required laboratory control mechanisms (21 CFR 211.160(a)).\nYou lacked adequate controls to assure the reliability of microbiological testing results. For example:\nA. Numerous non-viable dark particles were observed in (b)(4) plates used for microbiological analyses in your laboratory.\nB. Non-viable dark particles were observed on filter (b)(4) used for (b)(4) microbiological testing.\nC. Media plates prepared in-house did not consistently possess smooth surfaces needed to ensure maximum contact of test articles to facilitate the growth of any microbiological organisms present.\nD. Analysts did not consistently ensure filter (b)(4) on media plates during microbiological testing needed to ensure maximum contact of filter (b)(4) to facilitate the growth of any microbiological organisms present.\nIn your response, you indicate you discontinued use of, and discarded, the implicated filter (b)(4) lot associated with the observed particulate matter and are attempting to identify an alternate vendor. You also performed a retrospective review of (b)(4) testing data, and you do not identify any similar instances of air bubbles being observed during testing. You conclude any incidence of failing to ensure filter (b)(4) on media plates during testing are “rare” and do not impact product quality.\nYour response is inadequate. You do not holistically assess microbiological laboratory conditions and practices and their impact on the reliability of microbiological test results. Your retrospective review protocol to identify instances of (b)(4) filter (b)(4) during testing is insufficient as it relies on documentation of events that were not being recorded by your analysts. Additionally, the conclusion of the retrospective review stating there was no impact on product quality lacks scientific justification, in that contact between the filter (b)(4) and the media is essential for the growth and identification of any microbiological organisms on the filter (b)(4).\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA retrospective, independent review of all microbiological test data for products currently in the U.S. market and within expiry as of the date of this letter to assess the impact of the observed laboratory conditions and practices on the reliability of the microbiological test data. The review should include testing performed in support of qualification and validation activities currently relied upon to support the manufacture of drug products for the U.S. market.\nA comprehensive, independent review of your material system to determine whether all suppliers of equipment and test supplies are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable equipment and test supplies.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nOur review found deficiencies in video recordings of airflow (smoke) studies executed in the ISO 5 areas including on Line (b)(4) at the empty vial (b)(4) and the nozzle (b)(4). Specifically, the presence of excessive smoke prevented visualization of airflows. The inadequate visualization of airflow is a repeated from the 2023 inspection of your facility.\nIn your response, you commit to providing additional training to personnel responsible for the execution of airflow studies and to conduct new studies.\nYour response is inadequate. Your previous actions taken to prevent recurrence were inadequate. You do not commit to reassessing your training program or the failure of previously implemented corrective action and preventive action (CAPA) to remediate the airflow studies. In response to this letter, provide:\nAn independent assessment of the training provided to personnel responsible for the execution of airflow study protocols.\nAn independent assessment of the CAPA effectiveness in response to previous adverse findings associated with your conduct of airflow studies. The assessment should include the determination of root cause(s), CAPA, and a description of how the CAPA effectiveness will be determined.\nA revised Line (b)(4) airflow study protocol, completed protocol report, the airflow study videos, and an independent assessment of the aforementioned protocol, complete protocol report, and airflow study videos.\n3. Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions (21 CFR 211.42(c)(10)(vi)).\nOur review found unsuitable conditions in ISO 5 areas where aseptic processing is conducted. For example:\nA. Rough metal surfaces and an incomplete (b)(4) were observed on the Line (b)(4) Restricted Access Barrier System (RABS) framework in the area above the stopper loading chute.\nB. (b)(4) or (b)(4) were observed protruding through the interior of RABS (b)(4) on the Line (b)(4) RABS in the area above the stopper loading chute.\nC. (b)(4) conduit was present with exposed wires and not properly secured to the adjoining surface in the Line (b)(4) filtration area.\nYou previously remediated the Line (b)(4) RABS in response to the unsuitable physical condition of Line (b)(4) RABS (b)(4) documented in the 2023 inspection of this facility. Your remediation activities failed to wholistically address the conditions of the Line (b)(4) RABS.\nIn your response, you report Lines (b)(4) were inspected for additional “uneven rough surfaces,” commit to inspecting Lines (b)(4) in the future, and updating procedures to require the inspection of areas for the presence of uneven and rough surfaces. You report an inspection of Lines (b)(4) for areas that are difficult to clean and identified a root cause for the electrical conduit not being properly secured as “improper verification” of the conduit. You also report the conduct of “Awareness Training” of personnel in your Engineering department.\nYour response is inadequate. You do not:\nEvaluate the training of personnel responsible for inspection activities.\nPerform a comprehensive assessment of all lines and equipment therein to ensure appropriate design and suitability of materials of construction and equipment.\nComprehensively assess procedures governing equipment design to ensure appropriate user requirements are established.\nAssess the quality unit’s (QU) role in assuring the suitability of the facility and equipment therein.\nIn response to this letter, provide your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Explain how you will use qualified third-party consultant(s) to assist you in development, execution, and assessment of CAPA effectiveness for these activities.\n4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour investigations into product quality defect complaints are not consistently and scientifically supported and rely on flawed analyses to reach conclusions on product quality impact. For example:\nA. Your investigation into complaints of dispensing tip (nozzle) blockage associated with (b)(4) solution USP (b)(4)% ((b)(4)) and (b)(4) and (b)(4) solution USP, (b)(4)mg\u002Fml and (b)(4)mg\u002FmL ((b)(4)) concluded the tip blockage phenomena was due to improper storage by patients. You stated the ensuing exposure of product solutions to air resulted in the (b)(4) excipient in the formulations forming a film or precipitating and blocking the dispensing tips. Your investigation is deficient for reasons including, but not limited to:\n1. Neither of the scientific publication sources cited in your investigation support your root cause.\n2. Your experimental study compared the effect of atmospheric exposure of a freshly prepared solution by your research and development group against samples of innovator product that expired approximately 2.5 years earlier.\nB. Your investigations into complaints of (b)(4) and (b)(4) drug products missing tips or being received empty by patients were repeatedly determined to have no impact on product quality. This conclusion conflicts with the finished product quality attributes for fill volume.\nIn your response, you report your (b)(4). You also report the revision of your complaint handling procedure and your plan to evaluate the function of equipment used to detect missing container closure system components.\nYour response is inadequate. You do not provide sound scientific data or other relevant information supporting your conclusion that atmospheric exposure of (b)(4) in these products is solely responsible for the tip blockage complaints. You also did not adequately address empty units being received by patients.\nIn response to this letter, provide:\nA scientifically sound investigation into the tip blockage issue. The investigation should identify root cause(s), CAPA, and the mechanism(s) for determining CAPA effectiveness.\nAn independent evaluation of your product quality complaint handling procedures and practices including relevant procedures and practices used by contracted third parties that perform complaint handling activities on your behalf. The independent evaluation should include identification of all deficiencies, assignment of appropriate CAPA, and the mechanism(s) for determining CAPA effectiveness.\n5. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\nWarning and error messages in the Empower Message Center included in your chromatography data software are not reviewed. For example, during the 20-day period between December 26, 2023, and January 15, 2024, the following error messages were registered in the Empower Message Center:\nA. Approximately 33 instances of “Injection --- cannot be altered. It belongs to a sample set which is currently being acquired”\nB. Approximately 60 instances of “User Abort”\nC. Approximately 18 instances of “Stop Flow key was pressed”\nThe procedures governing chromatography analyses do not require the review of all audit trail data. Your personnel were unaware of the requirement to review the Empower Message Center data in Plant (b)(4) analyses during the inspection. The error and warning messages in the Empower Message Center can be an indicator of problems with equipment and method suitability.\nIn your response, you report revisions to the procedures governing chromatography analyses in Plant (b)(4) and Plant (b)(4) to require the review of data in the Empower Message Center. You also report the conduct of a “comprehensive review” of data in the Empower Message Center in Plant (b)(4) and Plant (b)(4) and corresponding risk assessments. You also indicate you do not review the Empower Message Center as required by your procedure governing chromatography analyses in Plant (b)(4).\nYour response is inadequate. Your review of data in the Empower Message Center failed to identify unexpected discrepancies including approximately 32 of the 33 instances of “Injection --- cannot be altered. It belongs to a sample set which is currently being acquired” messages generated between December 26, 2023, and January 15, 2024, were associated with the same user. You also did not identify and investigate the relatively high number of “User Abort” messages generated over the same timeframe.\nIn response to this letter, provide an independent, retrospective assessment of Empower Message Center data for the last three years from the initial date of inspection and a report summarizing the findings of the analysis. The analysis should include trending of pertinent data including, but not limited to, specific users, methods, and equipment.\nRepeat Violations at Facility\nIn a previous inspection, dated February 20 to February 28, 2023, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Indoco Remedies Ltd., L 32 33 - 34 I D C Verna Industrial Road, Vasco Da Gama, Goa, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005124189 and ATTN: Jason F. Chancey.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Indoco Remedies Limited","indoco-remedies-limited-691594-12162024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Findoco-remedies-limited-691594-12162024","2026-10-26T08:08:58.564717+00:00","2025-01-07","691594","Ms. Aditi Kare Panandikar","2026-08-19T17:05:51.067+00:00","Via Email","320-25-23","2024-12-16",{"id":73,"raw":74,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":62,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":88,"body_fetched_at":89,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},1132,[75,76,77,11,78,13,13,13],"\u003Ctime datetime=\"2024-12-17T14:20:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-10T05:00:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fxcel-research-llc-694608-12102024\">Xcel Research LLC\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew Pierce\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Xcel Research LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1309 Coffeen Ave., Suite 12238\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Support@XcelPeptides.com\"> Support@XcelPeptides.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>\u003Cu>WARNING LETTER\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 10, 2024\u003C\u002Fp>\u003Cp>RE: 694608\u003C\u002Fp>\u003Cp>Dear Andrew Pierce:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” for sale in the United States. As described below, your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products, “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>“RETA” (Retatrutide)\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Freta\u002F:\u003Cbr>• “Retatrutide, a triple agonist peptide, interacts with glucagon, GIP, and GLP-1 receptors. In clinical trials, it exhibits potential for weight management by regulating appetite and metabolism in research test subjects.”\u003Cbr>• “Enhanced Insulin Sensitivity . . . By enhancing insulin sensitivity, retatrutide peptide helps test subjects maintain stable blood glucose levels and reduces the risk of developing metabolic disorders associated with insulin resistance.”\u003Cbr>• “Cardiovascular Protection . . . [R]etatrutide peptide has been shown to improve endothelial function, reduce arterial stiffness, and lower blood pressure, thus reducing the risk of cardiovascular diseases such as hypertension and atherosclerosis.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“CagriLean” (Cagrilintide and Semaglutide)\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilean\u002F:\u003Cbr>• “Cagrilintide and semaglutide blend that aids test subjects in managing weight and improving blood sugar levels. This peptide combination helps research subjects feel fuller for longer, curbing their appetite and enhancing metabolic function.”\u003Cbr>• “Understanding Cagrilintide and Semaglutide . . . Cagrilintide is a synthetic peptide known for its ability to regulate appetite. It mimics the natural hormone amylin, which plays a crucial role in controlling hunger and food intake. On the other hand, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It has been extensively researched for its effects on glucose regulation and appetite suppression.”\u003Cbr>• “Enhanced Glucose Regulation . . . CagriLean helps maintain stable blood glucose levels, reducing the risk of glucose spikes and crashes. This can be instrumental in experiments focusing on insulin sensitivity, glucose metabolism, and the development of diabetes treatments.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“CAGRILINTIDE”\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilintide\u002F:\u003Cbr>• “Enhanced Glucose Control . . . By influencing the release of insulin and other hormones involved in glucose metabolism, it may help stabilize blood sugar levels. This effect could be beneficial for research test subjects with conditions such as diabetes or insulin resistance.”\u003Cbr>• “Improved Lipid Profile: Research suggests that Cagrilintide may also have favorable effects on lipid metabolism, leading to improvements in lipid profiles. By influencing the breakdown and utilization of fats, it may help lower levels of triglycerides and LDL cholesterol while increasing HDL cholesterol levels.”\u003Cbr>• “Cagrilintide exhibits a wide range of potential health benefits for research test subjects, spanning appetite regulation, glucose control, weight management, lipid metabolism, inflammation, cardiometabolic protection, neuroprotection, and the convenience of long-acting formulation.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“MAZDUTIDE”&nbsp;\u003C\u002Fstrong>&nbsp;\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fmazdutide\u002F:\u003Cbr>• “Mazdutide. . .[is] designed to mimic the actions of a hormone called glucagon-like peptide-1 (GLP-1). It offers numerous benefits in research subjects, such as improving blood sugar control by stimulating insulin secretion and reducing appetite. Additionally, it aids in weight management and may enhance cardiovascular health by lowering blood pressure and improving cholesterol levels.”\u003Cbr>• “Cardiovascular Health: Mazdutide exhibits cardioprotective effects, which could be advantageous for research test subjects at risk of cardiovascular diseases. GLP-1 receptor activation has been linked to improvements in cardiovascular function, such as reducing blood pressure and improving lipid profiles.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“SEMA” (Semaglutide)\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsema\u002F:\u003Cbr>• “Regulation of Blood Sugar Levels: Sema exhibits potent glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release, two crucial mechanisms in maintaining blood sugar balance.”\u003Cbr>• “Weight Loss and Appetite Suppression: . . . By acting on specific receptors in the brain, this peptide promotes satiety and reduces food intake, leading to decreased body weight and fat mass.”\u003Cbr>• “Neuroprotective Potential: Emerging evidence suggests that semaglutide peptide may possess neuroprotective properties, offering potential benefits in neurodegenerative diseases such as Alzheimer’s disease.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“SURVODUTIDE”\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsurvodutide\u002F:\u003Cbr>• “Survodutide. . .belongs to a class of drugs known as dual agonists, meaning it targets two different types of receptors in the body: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors play crucial roles in regulating various bodily functions, including metabolism, appetite, and blood sugar levels.”\u003Cbr>• “Health Benefits of Survodutide . . . Improved Blood Sugar Control[.] One of the most significant benefits of survodutide is its ability to improve blood sugar control in research lab subjects . . .. [I]t can help regulate blood glucose levels more effectively than targeting either receptor alone. In research subjects, this dual action has shown promise in stabilizing blood sugar levels, which is crucial for managing conditions like diabetes.\"\u003C\u002Fp>\u003Cp>\u003Cstrong>“SERMORELIN”&nbsp;\u003C\u002Fstrong>&nbsp;\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsermorelin\u002F:\u003Cbr>• “Sermorelin, a peptide studied in clinical trials, is believed to enhance the release of growth hormone in subjects. This heightened growth hormone production is associated with potential benefits, including improved metabolism and the facilitation of weight loss.”\u003Cbr>• “Enhanced Muscle Growth and Repair[.] One of the primary benefits observed in test subjects administered with sermorelin is enhanced muscle growth and repair.”\u003Cbr>• “Improved Metabolism and Fat Loss[.] Another notable benefit of sermorelin is its potential to improve metabolism and aid in fat loss.”\u003C\u002Fp>\u003Cp>Your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAndrew Pierce\n\nXcel Research LLC\n\n1309 Coffeen Ave., Suite 12238\n\nSheridan, WY 82801\n\nUnited States\n\nSupport@XcelPeptides.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 10, 2024\nRE: 694608\nDear Andrew Pierce:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” for sale in the United States. As described below, your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\nDespite statements on your product labeling marketing your products, “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\n“RETA” (Retatrutide)\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Freta\u002F:\n• “Retatrutide, a triple agonist peptide, interacts with glucagon, GIP, and GLP-1 receptors. In clinical trials, it exhibits potential for weight management by regulating appetite and metabolism in research test subjects.”\n• “Enhanced Insulin Sensitivity . . . By enhancing insulin sensitivity, retatrutide peptide helps test subjects maintain stable blood glucose levels and reduces the risk of developing metabolic disorders associated with insulin resistance.”\n• “Cardiovascular Protection . . . [R]etatrutide peptide has been shown to improve endothelial function, reduce arterial stiffness, and lower blood pressure, thus reducing the risk of cardiovascular diseases such as hypertension and atherosclerosis.”\n“CagriLean” (Cagrilintide and Semaglutide)\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilean\u002F:\n• “Cagrilintide and semaglutide blend that aids test subjects in managing weight and improving blood sugar levels. This peptide combination helps research subjects feel fuller for longer, curbing their appetite and enhancing metabolic function.”\n• “Understanding Cagrilintide and Semaglutide . . . Cagrilintide is a synthetic peptide known for its ability to regulate appetite. It mimics the natural hormone amylin, which plays a crucial role in controlling hunger and food intake. On the other hand, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It has been extensively researched for its effects on glucose regulation and appetite suppression.”\n• “Enhanced Glucose Regulation . . . CagriLean helps maintain stable blood glucose levels, reducing the risk of glucose spikes and crashes. This can be instrumental in experiments focusing on insulin sensitivity, glucose metabolism, and the development of diabetes treatments.”\n“CAGRILINTIDE”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilintide\u002F:\n• “Enhanced Glucose Control . . . By influencing the release of insulin and other hormones involved in glucose metabolism, it may help stabilize blood sugar levels. This effect could be beneficial for research test subjects with conditions such as diabetes or insulin resistance.”\n• “Improved Lipid Profile: Research suggests that Cagrilintide may also have favorable effects on lipid metabolism, leading to improvements in lipid profiles. By influencing the breakdown and utilization of fats, it may help lower levels of triglycerides and LDL cholesterol while increasing HDL cholesterol levels.”\n• “Cagrilintide exhibits a wide range of potential health benefits for research test subjects, spanning appetite regulation, glucose control, weight management, lipid metabolism, inflammation, cardiometabolic protection, neuroprotection, and the convenience of long-acting formulation.”\n“MAZDUTIDE”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fmazdutide\u002F:\n• “Mazdutide. . .[is] designed to mimic the actions of a hormone called glucagon-like peptide-1 (GLP-1). It offers numerous benefits in research subjects, such as improving blood sugar control by stimulating insulin secretion and reducing appetite. Additionally, it aids in weight management and may enhance cardiovascular health by lowering blood pressure and improving cholesterol levels.”\n• “Cardiovascular Health: Mazdutide exhibits cardioprotective effects, which could be advantageous for research test subjects at risk of cardiovascular diseases. GLP-1 receptor activation has been linked to improvements in cardiovascular function, such as reducing blood pressure and improving lipid profiles.”\n“SEMA” (Semaglutide)\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsema\u002F:\n• “Regulation of Blood Sugar Levels: Sema exhibits potent glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release, two crucial mechanisms in maintaining blood sugar balance.”\n• “Weight Loss and Appetite Suppression: . . . By acting on specific receptors in the brain, this peptide promotes satiety and reduces food intake, leading to decreased body weight and fat mass.”\n• “Neuroprotective Potential: Emerging evidence suggests that semaglutide peptide may possess neuroprotective properties, offering potential benefits in neurodegenerative diseases such as Alzheimer’s disease.”\n“SURVODUTIDE”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsurvodutide\u002F:\n• “Survodutide. . .belongs to a class of drugs known as dual agonists, meaning it targets two different types of receptors in the body: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors play crucial roles in regulating various bodily functions, including metabolism, appetite, and blood sugar levels.”\n• “Health Benefits of Survodutide . . . Improved Blood Sugar Control[.] One of the most significant benefits of survodutide is its ability to improve blood sugar control in research lab subjects . . .. [I]t can help regulate blood glucose levels more effectively than targeting either receptor alone. In research subjects, this dual action has shown promise in stabilizing blood sugar levels, which is crucial for managing conditions like diabetes.\"\n“SERMORELIN”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsermorelin\u002F:\n• “Sermorelin, a peptide studied in clinical trials, is believed to enhance the release of growth hormone in subjects. This heightened growth hormone production is associated with potential benefits, including improved metabolism and the facilitation of weight loss.”\n• “Enhanced Muscle Growth and Repair[.] One of the primary benefits observed in test subjects administered with sermorelin is enhanced muscle growth and repair.”\n• “Improved Metabolism and Fat Loss[.] Another notable benefit of sermorelin is its potential to improve metabolism and aid in fat loss.”\nYour “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Xcel Research LLC","xcel-research-llc-694608-12102024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fxcel-research-llc-694608-12102024","2026-10-26T08:10:34.731468+00:00","2024-12-17","694608","Andrew Pierce","2026-08-19T17:08:28.221+00:00","2024-12-10",{"id":92,"raw":93,"subject":98,"body_html":99,"body_text":100,"firm_name":101,"letter_id":102,"created_at":103,"fei_number":19,"letter_url":104,"updated_at":105,"action_type":22,"case_status":23,"posted_date":106,"marcs_cms_no":107,"product_type":108,"closeout_date":19,"issuing_office":97,"recipient_name":109,"body_fetched_at":110,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":111,"medical_device_id":19,"response_letter_date":19},192,[94,95,96,97,98,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-23T05:00:00Z\">01\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintelligent-remedies-inc-681941-01232026\">Intelligent Remedies, Inc.\u003C\u002Fa>","Human Foods Program","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Steven M. Schorr\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Intelligent Remedies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O Box 448\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puunene\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96784-0448\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@intelligentremedies.com\"> info@intelligentremedies.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 23, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #681941\u003C\u002Fp>\u003Cp>Dear Mr. Schorr:\u003C\u002Fp>\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fintelligentremedies.com\u002F in August and September 2025 and has determined that you take orders there for your products Pryenda, Athrombosyn, Ionophoric Zinc, CHAGAplus, Anxiety Support, Cardimyodin, VIRAsol, Curecumin, and HEMEflow O2. The claims on your website and on other product labeling establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Examples of some of the claims on your website, labels, and promotional materials that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Pryenda\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On the webpage titled “ANTI-VIRAL,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fimmune-boost:\u003C\u002Fp>\u003Cul>\u003Cli>“PRYENDA prevents and reverses cognitive damage caused from prions and is a therapeutic treatment against TSEs and other neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the product webpage for your Pryenda product, accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FPryenda-p518449037:\u003C\u002Fp>\u003Cul>\u003Cli>“Pryenda … known to stop the formation of prions in the brain.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the label of your Pryenda product:\u003C\u002Fp>\u003Cul>\u003Cli>“Pryenda extracts helps stop the production of prions (misfolded proteins) and may help restore brain function.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>From the Product Information Sheet shipped with orders of your Pryenda product:\u003C\u002Fp>\u003Cul>\u003Cli>“Pryenda™ is a Phytotherapeutic extraction of … phytochemicals … known to stop the formation of prions in the brain.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Athrombosyn\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On the webpage titled “ANTI-VIRAL,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fimmune-boost:\u003C\u002Fp>\u003Cul>\u003Cli>“Athrombosyn Phytotherapeutic Extract Formulation is designed to attenuate unwanted blood clotting in the cardiovascular system caused by inoculation-based sources. Contains [a formula of] phytotherapeutic extracts . . . known to attenuate blood clots.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the label of your Athrombosyn product:\u003C\u002Fp>\u003Cul>\u003Cli>“Anti-Clotting Extract”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Ionophoric Zinc\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On the label of your Ionophoric Zinc product:\u003C\u002Fp>\u003Cul>\u003Cli>“Organic Anti-Viral Zinc Extract”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the label of your Ionophoric Zinc product, as depicted on the product webpage, accessible at http:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FAntiviral-1-2-Punch-p518449021:\u003C\u002Fp>\u003Cul>\u003Cli>“Anti-Viral Extract”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>CHAGAplus\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On the product webpage for your CHAGAplus product, accessible at http:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FCHAGAplus-Immune-Support-Extract-p518449028 :\u003C\u002Fp>\u003Cul>\u003Cli>“CHAGAplus contains six of the most effective immune supporting herbs with proven effects against colds and influenza.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>From the promotional material entitled “Intelligent Remedies: Full Spectrum Anti-Viral Suite” shipped with orders of your products:\u003C\u002Fp>\u003Cul>\u003Cli>“CHAGAplusTM … contains six of the most effective immune supporting herbs with proven effects against colds and influenza …. [T]his formulation can help fight infections.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Anxiety Support\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On the webpage titled, “NURTURE,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fmaintain:\u003C\u002Fp>\u003Cul>\u003Cli>“Anxiety Support is specially formulated to combat anxiety and insomnia. It has other positive effects including … lowering your blood pressure …”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the label of your Anxiety Support product:\u003C\u002Fp>\u003Cul>\u003Cli>“Control Anxiety”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Cardimyodin\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On the label of your Cardimyodin product:\u003C\u002Fp>\u003Cul>\u003Cli>“Ingredients in Cardimyodin have been known to alleviate heart inflammation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>VIRAsol\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On the webpage titled “Antiviral 1-2 Punch,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FAntiviral-1-2-Punch-p518449021:\u003C\u002Fp>\u003Cul>\u003Cli>Under the heading “Product Details,” regarding your VIRAsol and Ionophoric Zinc products: “These two herbal antiviral extracts are powerhouses in the fight against viruses and the seasonal flu. Virasol™ is designed to stop the virus from getting in while Ionophoric Zn™ prevents infected cells from spreading to healthy ones.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the product webpage for your VIRAsol product, accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FVIRAsol-Antiviral-Extract-p518449042:\u003C\u002Fp>\u003Cul>\u003Cli>“VIRAsol is a blend of the two leading antiviral herbs … along with an array of distinct natural antiviral herbs proven effective against influenza swine flu, dengue, herpes, and HIV.”\u003C\u002Fli>\u003Cli>“Block the infection from taking hold by strengthening the cell wall”\u003C\u002Fli>\u003Cli>“Prevent the virus from docking with the cell”\u003C\u002Fli>\u003Cli>“Shorten the duration of respiratory symptoms”\u003C\u002Fli>\u003Cli>“Receive safe, natural, and effective treatment compared to Tamiflu.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the product label of VIRAsol:\u003C\u002Fp>\u003Cul>\u003Cli>“Organic Anti-Viral Extract”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>From the promotional material entitled “Intelligent Remedies: Full Spectrum Anti-Viral Suite,” shipped with orders of your products:\u003C\u002Fp>\u003Cul>\u003Cli>“Virasol contains six of the most effective herbs with proven effects against colds and influenza. These ingredients in this formulation are some of the most powerful herbs for preventing and treating colds and influenza. VIRAsol has been used to breakdown and destroy the protein sheath of a viral cell and help with anti-viral prevention.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Curecumin\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>On your website’s blog, in a post entitled “Why Curcumin\u002FTumeric is called ‘CUREcumin’ (5 reasons),” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fpost\u002Fturmeric-curcumin-curecumin (updated December 18, 2022):\u003C\u002Fp>\u003Cul>\u003Cli>Under the heading “What are the Benefits of Turmeric\u002FCurcumin?”:\u003Cbr>o “Viral Infections … HIV, Zika, Herpes, and HPV have all shown positive antiviral activity with Curcumin …. ”\u003Cbr>o “Depression … curcumin was shown to have benefits that were similar to Prozac ….”\u003Cbr>o “Cancer … Curcumin … has been found to affect tumor growth, development and spread ….”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>HEMEflow O2\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>From the promotional material entitled “Intelligent Remedies: Full Spectrum Anti-Viral Suite” shipped with new orders of your products:\u003C\u002Fp>\u003Cul>\u003Cli>“HEMEflow O2 … is used to treat a variety of blood-related ailments including blood deficiencies, uterine disorders, as well as ischemias of both the heart and brain … . These ingredients [in HEMEflow O2] help to treat and even prevent arthritis and other incidences of chronic inflammation … known to be anticancer, and anti-inflammatory.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your Pryenda, CHAGAplus, Anxiety Support, VIRAsol, Curecumin, and HEMEflow O2 products are intended for treatment of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Pryenda, CHAGAplus, Anxiety Support, VIRAsol, Curecumin, and HEMEflow O2 products fail to bear adequate directions for their intended use, and therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be addressed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplement@fda.hhs.gov. Please reference CMS # 681941 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Thomas Kuntz\u003Cbr>Acting Deputy Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Steven M. Schorr\n\nIntelligent Remedies, Inc.\n\nP.O Box 448\n\nPuunene, HI 96784-0448\n\nUnited States\n\ninfo@intelligentremedies.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJanuary 23, 2026\nWARNING LETTER\nCMS #681941\nDear Mr. Schorr:\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fintelligentremedies.com\u002F in August and September 2025 and has determined that you take orders there for your products Pryenda, Athrombosyn, Ionophoric Zinc, CHAGAplus, Anxiety Support, Cardimyodin, VIRAsol, Curecumin, and HEMEflow O2. The claims on your website and on other product labeling establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at http:\u002F\u002Fwww.fda.gov.\nExamples of some of the claims on your website, labels, and promotional materials that provide evidence that your products are intended for use as drugs include:\nPryenda\nOn the webpage titled “ANTI-VIRAL,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fimmune-boost:\n“PRYENDA prevents and reverses cognitive damage caused from prions and is a therapeutic treatment against TSEs and other neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.”\nOn the product webpage for your Pryenda product, accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FPryenda-p518449037:\n“Pryenda … known to stop the formation of prions in the brain.”\nOn the label of your Pryenda product:\n“Pryenda extracts helps stop the production of prions (misfolded proteins) and may help restore brain function.”\nFrom the Product Information Sheet shipped with orders of your Pryenda product:\n“Pryenda™ is a Phytotherapeutic extraction of … phytochemicals … known to stop the formation of prions in the brain.”\nAthrombosyn\nOn the webpage titled “ANTI-VIRAL,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fimmune-boost:\n“Athrombosyn Phytotherapeutic Extract Formulation is designed to attenuate unwanted blood clotting in the cardiovascular system caused by inoculation-based sources. Contains [a formula of] phytotherapeutic extracts . . . known to attenuate blood clots.”\nOn the label of your Athrombosyn product:\n“Anti-Clotting Extract”\nIonophoric Zinc\nOn the label of your Ionophoric Zinc product:\n“Organic Anti-Viral Zinc Extract”\nOn the label of your Ionophoric Zinc product, as depicted on the product webpage, accessible at http:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FAntiviral-1-2-Punch-p518449021:\n“Anti-Viral Extract”\nCHAGAplus\nOn the product webpage for your CHAGAplus product, accessible at http:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FCHAGAplus-Immune-Support-Extract-p518449028 :\n“CHAGAplus contains six of the most effective immune supporting herbs with proven effects against colds and influenza.”\nFrom the promotional material entitled “Intelligent Remedies: Full Spectrum Anti-Viral Suite” shipped with orders of your products:\n“CHAGAplusTM … contains six of the most effective immune supporting herbs with proven effects against colds and influenza …. [T]his formulation can help fight infections.”\nAnxiety Support\nOn the webpage titled, “NURTURE,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fmaintain:\n“Anxiety Support is specially formulated to combat anxiety and insomnia. It has other positive effects including … lowering your blood pressure …”\nOn the label of your Anxiety Support product:\n“Control Anxiety”\nCardimyodin\nOn the label of your Cardimyodin product:\n“Ingredients in Cardimyodin have been known to alleviate heart inflammation.”\nVIRAsol\nOn the webpage titled “Antiviral 1-2 Punch,” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FAntiviral-1-2-Punch-p518449021:\nUnder the heading “Product Details,” regarding your VIRAsol and Ionophoric Zinc products: “These two herbal antiviral extracts are powerhouses in the fight against viruses and the seasonal flu. Virasol™ is designed to stop the virus from getting in while Ionophoric Zn™ prevents infected cells from spreading to healthy ones.”\nOn the product webpage for your VIRAsol product, accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fstore\u002FVIRAsol-Antiviral-Extract-p518449042:\n“VIRAsol is a blend of the two leading antiviral herbs … along with an array of distinct natural antiviral herbs proven effective against influenza swine flu, dengue, herpes, and HIV.”\n“Block the infection from taking hold by strengthening the cell wall”\n“Prevent the virus from docking with the cell”\n“Shorten the duration of respiratory symptoms”\n“Receive safe, natural, and effective treatment compared to Tamiflu.”\nOn the product label of VIRAsol:\n“Organic Anti-Viral Extract”\nFrom the promotional material entitled “Intelligent Remedies: Full Spectrum Anti-Viral Suite,” shipped with orders of your products:\n“Virasol contains six of the most effective herbs with proven effects against colds and influenza. These ingredients in this formulation are some of the most powerful herbs for preventing and treating colds and influenza. VIRAsol has been used to breakdown and destroy the protein sheath of a viral cell and help with anti-viral prevention.”\nCurecumin\nOn your website’s blog, in a post entitled “Why Curcumin\u002FTumeric is called ‘CUREcumin’ (5 reasons),” accessible at https:\u002F\u002Fwww.intelligentremedies.com\u002Fpost\u002Fturmeric-curcumin-curecumin (updated December 18, 2022):\nUnder the heading “What are the Benefits of Turmeric\u002FCurcumin?”:\no “Viral Infections … HIV, Zika, Herpes, and HPV have all shown positive antiviral activity with Curcumin …. ”\no “Depression … curcumin was shown to have benefits that were similar to Prozac ….”\no “Cancer … Curcumin … has been found to affect tumor growth, development and spread ….”\nHEMEflow O2\nFrom the promotional material entitled “Intelligent Remedies: Full Spectrum Anti-Viral Suite” shipped with new orders of your products:\n“HEMEflow O2 … is used to treat a variety of blood-related ailments including blood deficiencies, uterine disorders, as well as ischemias of both the heart and brain … . These ingredients [in HEMEflow O2] help to treat and even prevent arthritis and other incidences of chronic inflammation … known to be anticancer, and anti-inflammatory.”\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour Pryenda, CHAGAplus, Anxiety Support, VIRAsol, Curecumin, and HEMEflow O2 products are intended for treatment of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Pryenda, CHAGAplus, Anxiety Support, VIRAsol, Curecumin, and HEMEflow O2 products fail to bear adequate directions for their intended use, and therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be addressed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplement@fda.hhs.gov. Please reference CMS # 681941 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nThomas Kuntz\nActing Deputy Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Intelligent Remedies, Inc.","intelligent-remedies-inc-681941-01232026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintelligent-remedies-inc-681941-01232026","2026-10-26T08:08:59.741591+00:00","2026-05-05","681941","DrugsFood & Beverages","Mr. Steven M. Schorr","2026-08-19T04:44:10.411+00:00","2026-01-23",{"id":113,"raw":114,"subject":79,"body_html":119,"body_text":120,"firm_name":121,"letter_id":122,"created_at":18,"fei_number":19,"letter_url":123,"updated_at":124,"action_type":22,"case_status":23,"posted_date":125,"marcs_cms_no":126,"product_type":127,"closeout_date":19,"issuing_office":118,"recipient_name":128,"body_fetched_at":129,"delivery_method":130,"recipient_title":19,"reference_number":131,"action_taken_date":132,"medical_device_id":19,"response_letter_date":19},884,[115,116,117,118,79,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-05T04:00:00Z\">05\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsupreme-rejuvenation-llc-700749-05052025\">Supreme Rejuvenation, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-700749\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Aracely Cabrera\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Supreme Rejuvenation, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11861 S Sam Houston Parkway, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77031\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@supremerejuvenation.com\"> info@supremerejuvenation.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 05, 2025\u003C\u002Fp>\u003Cp>CBER 25-700749\u003C\u002Fp>\u003Cp>Dear Aracely Cabrera:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s websites at www.supremerejuvenation.com and www.instagram.com\u002Fsupremeexosomes (last visited May 2025). Your website (www.supremerejuvenation.com) indicates that you sell “100 Billion Exosomes: Human Umbilical Cord Mesenchymal Stem Cell Derived Exosomes,” “15 ml 100 Billion Exosomes: Stem Cell Exosome Gel,” and “30 ml 200 Billion Exosomes: Stem Cell Exosome Gel” for allogeneic use (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information reviewed by FDA, including your websites, www.supremerejuvenation.com and www.instagram.com\u002Fsupremeexosomes (last visited May 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cp>• Homepage (www.supremerejuvenation.com)\u003Cbr>o Under a title, “ABOUT US”\u003Cbr> “Regenerative medicine products are designed to target inflammation and repair damaged tissues. They are intended for use in studies related to hair growth and wound care to addressing Traumatic Brain Injury, joint and ligament repair, Botox alternatives, IV infusions, various other conditions.”\u003Cbr>o Under a title, “SCAR REJUVENATION AND WOUND CURATION”\u003Cbr> “The exosome-based technology is designed to support the natural healing process by influencing cellular communication and tissue dynamics.”\u003Cbr> “Research suggests that these exosomes may influence collagen organization and fibroblast activity, which are key factors in skin repair.”\u003Cbr> “MSC-derived exosomes are believed to support tissue health through intercellular communication. These vesicles contain bioactive molecules that may promote cellular responses associated with tissue repair and regeneration.”\u003Cbr>o Under a title, “WHAT ARE EXOSOMES”\u003Cbr> “Exosomes act as nature’s messengers, facilitating intercellular communication. When they fuse with target cells, they deliver their payload, thereby kickstarting processes that promote tissue repair, regeneration, and growth.”\u003Cbr>o Under a title, “HOW THEY WORK”\u003Cbr> “Stem cell-derived exosomes have shown incredible efficacy in various studies, from peripheral nerve damage and traumatic brain injury to wound healing, bone fusion, and more. They possess anti-inflammatory properties and play vital roles in skin, cartilage, and bone regeneration, making them versatile assets in regenerative medicine.”\u003Cbr>o Under a title, “RESEARCH RESULTS”\u003Cbr> “Emerging research suggests that exosomes may play a role in cellular signaling, tissue dynamics, and physiological processes. Studies are investigating their potential influence on skin health, tissue remodeling, and other areas of regenerative science. Additionally, ongoing research continues to examine how exosomes may contribute to broader applications in fields such as cardiology, aesthetics, and neurological research.”\u003Cbr> “In the field of aesthetics, the exosomes have been shown to improve skin texture, reduce wrinkles, and stimulate hair growth. In a study conducted by Dr. Berman, the exosomes were found to stimulate hair growth in patients with androgenetic alopecia.”\u003Cbr> “Furthermore, the exosomes have been shown to have neuro-protective effects and can promote nerve regeneration in conditions such as optic nerve damage and glaucoma. Studies have also shown that the exosomes can improve symptoms in patients with COVID-19 long-haulers and dementia.”\u003Cbr> “In orthopedics, the exosomes have been shown to reduce inflammation and promote cartilage regeneration, making them effective in treating arthritis and other joint-related conditions. The exosomes have also been shown to improve outcomes in spinal cord injuries.”\u003Cbr>• Instagram page (www.instagram.com\u002Fsupremeexosomes)\u003Cbr>o With an image titled, “How can Exosome Therapy Benefit Women’s Health,” a caption from your firm states, “Exosome therapy offers exciting possibilities for women’s health! From reducing wrinkles, fine lines, and sagging skin to relieving menopausal symptoms like hot flashes and vaginal dryness, this innovative treatment can rejuvenate and restore balance… Discover how exosome therapy can help you feel your best-call us ... today.”\u003Cbr>o “Exosomes have an anti-inflammatory effect which is beneficial for wound and scar healing and treating conditions such as psoriasis, eczema, rosacea and acne.”\u003Cbr>o “A diabetic patient that does an Exosome IV injection has been known to decrease their dependency of Insulin injections as soon as two weeks.”\u003Cbr>o A video titled, “Exosome therapy for Fibromyalgia” with a caption from your firm states, “Say Goodbye to Fibromyalgia with Exosome Therapy! … Imagine a life where your body can begin to heal and your symptoms finally ease. Enter Exosome Therapy—a cutting-edge, natural treatment that’s changing lives… Why is Exosome Therapy a Game-Changer for Fibromyalgia? ∙Targets Inflammation at its Source…Promotes Cellular Repair…Contact us today…to…find out how this revolutionary treatment can work for you.”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect, 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements, 21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312. Although your website, www.supremerejuvenation.com, includes statements that your products are for “research and investigational purposes and are not approved for general medical use,” there is no IND in effect for your product. Nor is there a valid biologics license.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-700749\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nAracely Cabrera\n\nRecipient Title\n\nChief Executive Officer\n\nSupreme Rejuvenation, LLC\n\n11861 S Sam Houston Parkway, Suite A\n\nHouston, TX 77031\n\nUnited States\n\ninfo@supremerejuvenation.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nMay 05, 2025\nCBER 25-700749\nDear Aracely Cabrera:\nThe United States Food and Drug Administration (FDA) reviewed your company’s websites at www.supremerejuvenation.com and www.instagram.com\u002Fsupremeexosomes (last visited May 2025). Your website (www.supremerejuvenation.com) indicates that you sell “100 Billion Exosomes: Human Umbilical Cord Mesenchymal Stem Cell Derived Exosomes,” “15 ml 100 Billion Exosomes: Stem Cell Exosome Gel,” and “30 ml 200 Billion Exosomes: Stem Cell Exosome Gel” for allogeneic use (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information reviewed by FDA, including your websites, www.supremerejuvenation.com and www.instagram.com\u002Fsupremeexosomes (last visited May 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\n• Homepage (www.supremerejuvenation.com)\no Under a title, “ABOUT US”\n “Regenerative medicine products are designed to target inflammation and repair damaged tissues. They are intended for use in studies related to hair growth and wound care to addressing Traumatic Brain Injury, joint and ligament repair, Botox alternatives, IV infusions, various other conditions.”\no Under a title, “SCAR REJUVENATION AND WOUND CURATION”\n “The exosome-based technology is designed to support the natural healing process by influencing cellular communication and tissue dynamics.”\n “Research suggests that these exosomes may influence collagen organization and fibroblast activity, which are key factors in skin repair.”\n “MSC-derived exosomes are believed to support tissue health through intercellular communication. These vesicles contain bioactive molecules that may promote cellular responses associated with tissue repair and regeneration.”\no Under a title, “WHAT ARE EXOSOMES”\n “Exosomes act as nature’s messengers, facilitating intercellular communication. When they fuse with target cells, they deliver their payload, thereby kickstarting processes that promote tissue repair, regeneration, and growth.”\no Under a title, “HOW THEY WORK”\n “Stem cell-derived exosomes have shown incredible efficacy in various studies, from peripheral nerve damage and traumatic brain injury to wound healing, bone fusion, and more. They possess anti-inflammatory properties and play vital roles in skin, cartilage, and bone regeneration, making them versatile assets in regenerative medicine.”\no Under a title, “RESEARCH RESULTS”\n “Emerging research suggests that exosomes may play a role in cellular signaling, tissue dynamics, and physiological processes. Studies are investigating their potential influence on skin health, tissue remodeling, and other areas of regenerative science. Additionally, ongoing research continues to examine how exosomes may contribute to broader applications in fields such as cardiology, aesthetics, and neurological research.”\n “In the field of aesthetics, the exosomes have been shown to improve skin texture, reduce wrinkles, and stimulate hair growth. In a study conducted by Dr. Berman, the exosomes were found to stimulate hair growth in patients with androgenetic alopecia.”\n “Furthermore, the exosomes have been shown to have neuro-protective effects and can promote nerve regeneration in conditions such as optic nerve damage and glaucoma. Studies have also shown that the exosomes can improve symptoms in patients with COVID-19 long-haulers and dementia.”\n “In orthopedics, the exosomes have been shown to reduce inflammation and promote cartilage regeneration, making them effective in treating arthritis and other joint-related conditions. The exosomes have also been shown to improve outcomes in spinal cord injuries.”\n• Instagram page (www.instagram.com\u002Fsupremeexosomes)\no With an image titled, “How can Exosome Therapy Benefit Women’s Health,” a caption from your firm states, “Exosome therapy offers exciting possibilities for women’s health! From reducing wrinkles, fine lines, and sagging skin to relieving menopausal symptoms like hot flashes and vaginal dryness, this innovative treatment can rejuvenate and restore balance… Discover how exosome therapy can help you feel your best-call us ... today.”\no “Exosomes have an anti-inflammatory effect which is beneficial for wound and scar healing and treating conditions such as psoriasis, eczema, rosacea and acne.”\no “A diabetic patient that does an Exosome IV injection has been known to decrease their dependency of Insulin injections as soon as two weeks.”\no A video titled, “Exosome therapy for Fibromyalgia” with a caption from your firm states, “Say Goodbye to Fibromyalgia with Exosome Therapy! … Imagine a life where your body can begin to heal and your symptoms finally ease. Enter Exosome Therapy—a cutting-edge, natural treatment that’s changing lives… Why is Exosome Therapy a Game-Changer for Fibromyalgia? ∙Targets Inflammation at its Source…Promotes Cellular Repair…Contact us today…to…find out how this revolutionary treatment can work for you.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect, 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements, 21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312. Although your website, www.supremerejuvenation.com, includes statements that your products are for “research and investigational purposes and are not approved for general medical use,” there is no IND in effect for your product. Nor is there a valid biologics license.\nAdditional Concerns\nWe direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research","Supreme Rejuvenation, LLC","supreme-rejuvenation-llc-700749-05052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsupreme-rejuvenation-llc-700749-05052025","2026-10-26T08:10:08.108125+00:00","2025-05-20","700749","Biologics","Aracely Cabrera","2026-08-19T16:46:44.282+00:00","VIA UPS and Electronic Mail","CBER 25-700749","2025-05-05",{"id":134,"raw":135,"subject":138,"body_html":139,"body_text":140,"firm_name":141,"letter_id":142,"created_at":18,"fei_number":19,"letter_url":143,"updated_at":144,"action_type":22,"case_status":23,"posted_date":125,"marcs_cms_no":145,"product_type":146,"closeout_date":19,"issuing_office":97,"recipient_name":147,"body_fetched_at":148,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":149,"medical_device_id":19,"response_letter_date":19},888,[115,136,137,97,138,13,13,13],"\u003Ctime datetime=\"2025-04-15T04:00:00Z\">04\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgluten-free-remedies-llc-687832-04152025\">Gluten Free Remedies LLC\u003C\u002Fa>","Dietary Supplement\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alex Shikhman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gluten Free Remedies LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4125 Sorrento Valley Boulevard Ste A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@glutenfreeremedies.com\"> info@glutenfreeremedies.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 15, 2025\u003C\u002Fp>\u003Cp>CMS #687832\u003C\u002Fp>\u003Cp>Dear Mr. Shikhman,\u003C\u002Fp>\u003Cp>This letter concerns your product Sulbutiamine Plus Brain Support, which is labeled as a dietary supplement. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the Act) because this product is a misbranded dietary supplement. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>The label of your product Sulbutiamine Plus Brain Support declares sulbutiamine as a dietary ingredient; however, sulbutiamine is not a dietary ingredient. Under section 201(ff)(1) of the Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Sulbutiamine does not qualify as a dietary ingredient under section 201(ff)(1) of the Act because it is not a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Declaring sulbutiamine on your product label as a dietary ingredient causes your product to be misbranded under section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false or misleading in any particular.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of any food that is misbranded is a prohibited act under section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed via email to Quyen Tien, Compliance Officer, at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #687832 on any submissions and within the subject line of any emails to us. If you have any questions, you may also email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Laura Akowuah, JD, MPH\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This warning letter does not address whether sulbutiamine can be lawfully marketed in dietary supplements as a non-dietary ingredient. For non-dietary ingredients used in dietary supplements, the substance must be used in accordance with a food additive regulation or be generally recognized as safe (GRAS) for its intended use or qualify for another exception from the food additive definition (see section 201(s) of the Act [21 U.S.C. § 321(s)]).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAlex Shikhman\n\nRecipient Title\n\nCEO\u002FFounder\n\nGluten Free Remedies LLC\n\n4125 Sorrento Valley Boulevard Ste A\n\nSan Diego, CA 92121\n\nUnited States\n\ninfo@glutenfreeremedies.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nApril 15, 2025\nCMS #687832\nDear Mr. Shikhman,\nThis letter concerns your product Sulbutiamine Plus Brain Support, which is labeled as a dietary supplement. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the Act) because this product is a misbranded dietary supplement. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\nThe label of your product Sulbutiamine Plus Brain Support declares sulbutiamine as a dietary ingredient; however, sulbutiamine is not a dietary ingredient. Under section 201(ff)(1) of the Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Sulbutiamine does not qualify as a dietary ingredient under section 201(ff)(1) of the Act because it is not a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Declaring sulbutiamine on your product label as a dietary ingredient causes your product to be misbranded under section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false or misleading in any particular.1 The introduction or delivery for introduction into interstate commerce of any food that is misbranded is a prohibited act under section 301(a) of the Act [21 U.S.C. § 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed via email to Quyen Tien, Compliance Officer, at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #687832 on any submissions and within the subject line of any emails to us. If you have any questions, you may also email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLaura Akowuah, JD, MPH\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\nFood and Drug Administration\n_____________________\n1 This warning letter does not address whether sulbutiamine can be lawfully marketed in dietary supplements as a non-dietary ingredient. For non-dietary ingredients used in dietary supplements, the substance must be used in accordance with a food additive regulation or be generally recognized as safe (GRAS) for its intended use or qualify for another exception from the food additive definition (see section 201(s) of the Act [21 U.S.C. § 321(s)]).","Gluten Free Remedies LLC","gluten-free-remedies-llc-687832-04152025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgluten-free-remedies-llc-687832-04152025","2026-10-26T08:08:47.230028+00:00","687832","Dietary Supplements","Alex Shikhman","2026-08-19T16:45:54.254+00:00","2025-04-15",{"id":151,"raw":152,"subject":37,"body_html":156,"body_text":157,"firm_name":158,"letter_id":159,"created_at":103,"fei_number":19,"letter_url":160,"updated_at":161,"action_type":22,"case_status":23,"posted_date":162,"marcs_cms_no":163,"product_type":164,"closeout_date":19,"issuing_office":11,"recipient_name":165,"body_fetched_at":166,"delivery_method":167,"recipient_title":19,"reference_number":168,"action_taken_date":169,"medical_device_id":19,"response_letter_date":19},467,[153,154,155,11,37,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-04T05:00:00Z\">11\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsiddha-flower-essences-llc-dba-siddha-remedies-713217-11042025\">Siddha Flower Essences, LLC., dba Siddha Remedies\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-14\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael S. Deland\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO and Founder \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Siddha Flower Essences, LLC., dba Siddha Remedies\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2350 Eastman Ave, Suite 107\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oxnard\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93030\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-14\u003C\u002Fp>\u003Cp>November 4, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Deland:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Siddha Flower Essences, LLC., dba Siddha Remedies, FEI 3014145088, at 2350 Eastman Ave., Suite 107, Oxnard, from April 22 to 29, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your human and animal drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that you failed to update your human over-the-counter (OTC) homeopathic drug listings as required under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207.\u003C\u002Fp>\u003Cp>Thus, your drugs are not properly listed, and your firm has not fulfilled its listing obligations under 510(j) of the FD&amp;C Act, U.S.C. 360(j), and 21 CFR 207, which is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your May 20, 2025 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Charges\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals. Your firm also failed to conduct microbiological testing before use of each lot of a component with potential for objectionable microbiological contamination in light of its intended use (21 CFR 211.84(d)(1) and 211.84(d)(2)) and (21 CFR 211.84(d)(6)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture aqueous oral homeopathic drug products intended for children as young as 2 years old.\u003C\u002Fp>\u003Cp>\u003Cem>Purified Water\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to test your purchased bulk water to assure it was of acceptable quality for use in drug production. You also failed to establish the reliability of your component supplier at appropriate intervals. Your firm has not demonstrated that the water was suitable for its intended use and minimally met the USP purified water monograph.\u003C\u002Fp>\u003Cp>Pharmaceutical-grade water must be suitable for its intended use. Each lot must be tested to ensure conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts as well as characterization and identification of contamination is integral to ensuring water is of acceptable quality for use in manufacturing operations.\u003C\u002Fp>\u003Cp>Of particular note, you stopped testing the water after 2022, but you continued to use it as a component of your pediatric drug products. Prior to stopping, you did not test the water for \u003Cem>Burkholderia cepacia complex\u003C\u002Fem> (BCC), a contamination risk in non-sterile water-based drug products, which has been linked to multiple instances of opportunistic infections. For further information regarding the significance of BCC and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice, at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile.\u003C\u002Fp>\u003Cp>\u003Cem>Botanical\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to perform adequate testing of botanical components that may pose potentially toxic effects. Without adequate component controls, you lack scientific evidence to assure component identity, safety, quality, and conformance to appropriate specifications.\u003C\u002Fp>\u003Cp>In your response, you acknowledge insufficient expertise, quality unit (QU) oversight, and resources. You also commit to improving component controls (e.g., specifications, procedures, testing) and propose various timelines for completion. However, you did not provide clear interim plans for drug production until corrections are completed. Also, you have not confirmed the reliability of your contract testing laboratories, nor have you evaluated the impact of using inadequately controlled components on the quality and safety of drug products distributed within the United States.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system including, but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003Cbr>o a summary of your systemic corrective action and preventive action (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of the components you use in manufacturing and corresponding test results (e.g., total counts, identification to detect objectionable microbes, such as BCC).\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately investigate finished drug product sample results that were out of limit (OOL) for microbiological contamination. For example, you failed to identify a root cause and implement adequate CAPA. You state that you have rejected and destroyed the contaminated batch, however, you could not provide supporting documentation.\u003C\u002Fp>\u003Cp>You also failed to characterize and identify gram-negative growth recovered in finished drug product samples to evaluate whether it is objectionable based on intended use. Microbiological contamination of aqueous drug products poses an unacceptable risk to children as gram-negative bacteria have been linked to opportunistic infections.\u003C\u002Fp>\u003Cp>In your response, you state your firm lacks qualified personnel and has insufficient QU oversight and resources. You also commit to performing CAPA including a retrospective review of discrepancies for potential product impact. However, your response in inadequate. You did not provide a clear timeline for CAPA completion (e.g., BCC testing) or clear interim plans for drug production until you determine the full scope of impact to drug quality and safety.\u003C\u002Fp>\u003Cp>Well-documented, thorough, and scientifically sound investigations are necessary to identify the root cause and implement appropriate and effective CAPA.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations of all batches with potential objectionable microbial contamination or an out-of-limit (OOL) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>Appropriate microbiological batch release specifications (e.g., total counts, identification of bioburden to detect objectionable microbes, such as BCC) for each of your drug products including the specific date test results indicated drug products met all specifications.\u003C\u002Fli>\u003Cli>All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective action you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm released finished drug product Temper Tamer lot# S22-26424D without testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms). Without testing each batch prior to release, you did not have scientific evidence that all oral drug product batches were free of objectionable microbial contamination.\u003C\u002Fp>\u003Cp>In particular, your firm failed to conduct testing for BCC for non-sterile aqueous-based drug products at release and on stability. See FDA’s advisory notice mentioned above. In addition, see FDA’s guidance document, \u003Cem>Microbiological Quality Considerations in Non-sterile Drug Manufacturing\u003C\u002Fem>, for help minimizing the risks of harmful microbiological contamination of aqueous drugs at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fmicrobiological-quality-considerations-non-sterile-drug-manufacturing.\u003C\u002Fp>\u003Cp>We acknowledge that you voluntarily initiated a recall of pediatric drug product Temper Tamer lot# S22-26424D on April 28, 2025. However, it is important to note that this CGMP violation was identified by your firm as a result of an FDA inspection conducted from April 25 to 29, 2025.\u003C\u002Fp>\u003Cp>In your response, you acknowledge insufficient QU oversight, lack of qualified personnel, and lack of adherence to procedures. You also commit to improving finished product controls (e.g., specifications, procedures, testing), conducting a retrospective review, and proposing various completion dates. However, several details remain unclear. This includes, but is not limited to, a clear timeline for CAPA completion (e.g., BCC testing) and interim plans for your operations while you determine the full scope of the impact of your violations on the quality and safety of the drugs you produce.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective action, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your QU did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Established procedures were followed (21 CFR 211.22(d))\u003C\u002Fli>\u003Cli>Batch records were reviewed before drug product release (21 CFR 211.22(a))\u003C\u002Fli>\u003Cli>Use of qualified contract testing laboratories (21 CFR 211.22(a))\u003C\u002Fli>\u003Cli>Adequate effectiveness testing of the preservative system (21 CFR 211.160(b))\u003C\u002Fli>\u003Cli>Adequate production and process controls were established (21 CFR 211.100(a))\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A description of how top management supports quality assurance and reliable operations including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Establishment Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510 of the FD&amp;C Act, 21 U.S.C. 360, and 21 CFR Part 207 set forth the requirements for the registration of establishments and listing of drugs. Under 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2) registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1st through December 31st annual registration period. If the drug listing data is not updated or certified, the outdated listing data will be inactivated at the next scheduled FDA inactivation period.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> You failed to update or certify your human OTC homeopathic drug listings as required.\u003C\u002Fp>\u003Cp>Therefore, your human OTC homeopathic drugs are not properly listed under section 510(j) of the FD&amp;C Act, rendering these drugs misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). In addition, failure to properly list a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>We note that during the inspection, your firm was notified that your human OTC homeopathic drugs were listed as “Inactivated-Uncertified” in eDRLS, and you have failed to update these drug listings. If you cease manufacturing and distributing any drug, then you must discontinue that listed drug in eDRLS by adding an end marketing date which corresponds to the expiration date of the last lot in commercial distribution. It is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at \u003Cem>\u003Cu>Electronic Drug Registration and Listing Instructions\u003C\u002Fu>\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>Sections 510(b)(1) and (j)(1) of the FD&amp;C Act [21 U.S.C. 360(b)(1), (j)(1)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in an establishment that is not duly registered or that have not been listed with FDA are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You have been manufacturing animal drugs in a facility that is not registered with FDA as an animal drug manufacturer. Further, you have incorrectly listed your animal drug products under the human drug establishment registration. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective action and preventive action before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014145088 and ATTN: CDR Matthew Schnupp, PharmD, BCSCP.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dillard H. Woody Jr.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance &amp; Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-14\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael S. Deland\n\nRecipient Title\n\nCEO and Founder\n\nSiddha Flower Essences, LLC., dba Siddha Remedies\n\n2350 Eastman Ave, Suite 107\n\nOxnard, CA 93030\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWarning Letter 320-26-14\nNovember 4, 2025\nDear Mr. Deland:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Siddha Flower Essences, LLC., dba Siddha Remedies, FEI 3014145088, at 2350 Eastman Ave., Suite 107, Oxnard, from April 22 to 29, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your human and animal drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that you failed to update your human over-the-counter (OTC) homeopathic drug listings as required under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207.\nThus, your drugs are not properly listed, and your firm has not fulfilled its listing obligations under 510(j) of the FD&C Act, U.S.C. 360(j), and 21 CFR 207, which is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p), and will render a drug misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nWe reviewed your May 20, 2025 response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\nCGMP Charges\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals. Your firm also failed to conduct microbiological testing before use of each lot of a component with potential for objectionable microbiological contamination in light of its intended use (21 CFR 211.84(d)(1) and 211.84(d)(2)) and (21 CFR 211.84(d)(6)).\nYou manufacture aqueous oral homeopathic drug products intended for children as young as 2 years old.\nPurified Water\nYou failed to test your purchased bulk water to assure it was of acceptable quality for use in drug production. You also failed to establish the reliability of your component supplier at appropriate intervals. Your firm has not demonstrated that the water was suitable for its intended use and minimally met the USP purified water monograph.\nPharmaceutical-grade water must be suitable for its intended use. Each lot must be tested to ensure conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts as well as characterization and identification of contamination is integral to ensuring water is of acceptable quality for use in manufacturing operations.\nOf particular note, you stopped testing the water after 2022, but you continued to use it as a component of your pediatric drug products. Prior to stopping, you did not test the water for Burkholderia cepacia complex (BCC), a contamination risk in non-sterile water-based drug products, which has been linked to multiple instances of opportunistic infections. For further information regarding the significance of BCC and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice, at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile.\nBotanical\nYou also failed to perform adequate testing of botanical components that may pose potentially toxic effects. Without adequate component controls, you lack scientific evidence to assure component identity, safety, quality, and conformance to appropriate specifications.\nIn your response, you acknowledge insufficient expertise, quality unit (QU) oversight, and resources. You also commit to improving component controls (e.g., specifications, procedures, testing) and propose various timelines for completion. However, you did not provide clear interim plans for drug production until corrections are completed. Also, you have not confirmed the reliability of your contract testing laboratories, nor have you evaluated the impact of using inadequately controlled components on the quality and safety of drug products distributed within the United States.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system including, but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\no a summary of your systemic corrective action and preventive action (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of the components you use in manufacturing and corresponding test results (e.g., total counts, identification to detect objectionable microbes, such as BCC).\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou failed to adequately investigate finished drug product sample results that were out of limit (OOL) for microbiological contamination. For example, you failed to identify a root cause and implement adequate CAPA. You state that you have rejected and destroyed the contaminated batch, however, you could not provide supporting documentation.\nYou also failed to characterize and identify gram-negative growth recovered in finished drug product samples to evaluate whether it is objectionable based on intended use. Microbiological contamination of aqueous drug products poses an unacceptable risk to children as gram-negative bacteria have been linked to opportunistic infections.\nIn your response, you state your firm lacks qualified personnel and has insufficient QU oversight and resources. You also commit to performing CAPA including a retrospective review of discrepancies for potential product impact. However, your response in inadequate. You did not provide a clear timeline for CAPA completion (e.g., BCC testing) or clear interim plans for drug production until you determine the full scope of impact to drug quality and safety.\nWell-documented, thorough, and scientifically sound investigations are necessary to identify the root cause and implement appropriate and effective CAPA.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations of all batches with potential objectionable microbial contamination or an out-of-limit (OOL) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\nAppropriate microbiological batch release specifications (e.g., total counts, identification of bioburden to detect objectionable microbes, such as BCC) for each of your drug products including the specific date test results indicated drug products met all specifications.\nAll chemical and microbial test methods used to analyze each of your drug products.\nA summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective action you will take, including notifying customers and initiating recalls.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\nYour firm released finished drug product Temper Tamer lot# S22-26424D without testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms). Without testing each batch prior to release, you did not have scientific evidence that all oral drug product batches were free of objectionable microbial contamination.\nIn particular, your firm failed to conduct testing for BCC for non-sterile aqueous-based drug products at release and on stability. See FDA’s advisory notice mentioned above. In addition, see FDA’s guidance document, Microbiological Quality Considerations in Non-sterile Drug Manufacturing, for help minimizing the risks of harmful microbiological contamination of aqueous drugs at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fmicrobiological-quality-considerations-non-sterile-drug-manufacturing.\nWe acknowledge that you voluntarily initiated a recall of pediatric drug product Temper Tamer lot# S22-26424D on April 28, 2025. However, it is important to note that this CGMP violation was identified by your firm as a result of an FDA inspection conducted from April 25 to 29, 2025.\nIn your response, you acknowledge insufficient QU oversight, lack of qualified personnel, and lack of adherence to procedures. You also commit to improving finished product controls (e.g., specifications, procedures, testing), conducting a retrospective review, and proposing various completion dates. However, several details remain unclear. This includes, but is not limited to, a clear timeline for CAPA completion (e.g., BCC testing) and interim plans for your operations while you determine the full scope of the impact of your violations on the quality and safety of the drugs you produce.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective action, such as notifying customers and product recalls.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour QU did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure:\nEstablished procedures were followed (21 CFR 211.22(d))\nBatch records were reviewed before drug product release (21 CFR 211.22(a))\nUse of qualified contract testing laboratories (21 CFR 211.22(a))\nAdequate effectiveness testing of the preservative system (21 CFR 211.160(b))\nAdequate production and process controls were established (21 CFR 211.100(a))\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA description of how top management supports quality assurance and reliable operations including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\nEstablishment Registration and Drug Listing Violations\nSection 510 of the FD&C Act, 21 U.S.C. 360, and 21 CFR Part 207 set forth the requirements for the registration of establishments and listing of drugs. Under 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2) registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1st through December 31st annual registration period. If the drug listing data is not updated or certified, the outdated listing data will be inactivated at the next scheduled FDA inactivation period.1 You failed to update or certify your human OTC homeopathic drug listings as required.\nTherefore, your human OTC homeopathic drugs are not properly listed under section 510(j) of the FD&C Act, rendering these drugs misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). In addition, failure to properly list a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\nWe note that during the inspection, your firm was notified that your human OTC homeopathic drugs were listed as “Inactivated-Uncertified” in eDRLS, and you have failed to update these drug listings. If you cease manufacturing and distributing any drug, then you must discontinue that listed drug in eDRLS by adding an end marketing date which corresponds to the expiration date of the last lot in commercial distribution. It is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\nSections 510(b)(1) and (j)(1) of the FD&C Act [21 U.S.C. 360(b)(1), (j)(1)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in an establishment that is not duly registered or that have not been listed with FDA are misbranded under section 502(o) of the FD&C Act.\nYou have been manufacturing animal drugs in a facility that is not registered with FDA as an animal drug manufacturer. Further, you have incorrectly listed your animal drug products under the human drug establishment registration. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective action and preventive action before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nUse of Contract Manufacturers\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014145088 and ATTN: CDR Matthew Schnupp, PharmD, BCSCP.\nSincerely,\n\u002FS\u002F\nJill P. Furman, J.D.\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nDillard H. Woody Jr.\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance & Compliance\nCenter for Veterinary Medicine\n______________________\n1 See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).","Siddha Flower Essences, LLC., dba Siddha Remedies","siddha-flower-essences-llc-dba-siddha-remedies-713217-11042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsiddha-flower-essences-llc-dba-siddha-remedies-713217-11042025","2026-10-26T08:09:57.454991+00:00","2025-11-18","713217","Drugs Over-the-Counter Drugs","Mr. Michael S. Deland","2026-08-19T14:55:23.85+00:00","VIA UPS","320-26-14","2025-11-04",{"id":171,"raw":172,"subject":177,"body_html":178,"body_text":179,"firm_name":180,"letter_id":181,"created_at":103,"fei_number":19,"letter_url":182,"updated_at":183,"action_type":22,"case_status":23,"posted_date":184,"marcs_cms_no":185,"product_type":186,"closeout_date":19,"issuing_office":176,"recipient_name":187,"body_fetched_at":188,"delivery_method":189,"recipient_title":19,"reference_number":19,"action_taken_date":190,"medical_device_id":19,"response_letter_date":19},272,[173,174,175,176,177,13,13,13],"\u003Ctime datetime=\"2026-03-10T04:00:00Z\">03\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-19T05:00:00Z\">02\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fel-rey-usa-meats-seafood-inc-722157-02192026\">El Rey USA Meats &amp; Seafood Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Daniel Leon Sr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>El Rey USA Meats &amp; Seafood Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2101 W. 74th St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chicago\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60636-3652\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 19, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS# 722157\u003C\u002Fp>\u003Cp>Dear Mr. Daniel Leon Sr.,\u003C\u002Fp>\u003Cp>We inspected your seafood importer establishment, located at 2101 W. 74th St. Chicago, IL., 60636-3652 on January 5, 2026, through January 9, 2026. We conducted a previous inspection on November 15, 2022, through November 17, 2022, which resulted in your firm receiving a letter from FDA dated January 23, 2023, that explained your firm’s non-compliance with the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations Part 123 (21 CFR Part 123). This current follow-up inspection found that your firm still has serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). The specific requirements for imported fish and fishery products are set out in 21 CFR 123.12.\u003C\u002Fp>\u003Cp>As an importer of fish or fishery products, you must operate in accordance with the requirements of Part 123. In accordance with 21 CFR 123.12(d), there must be evidence that all fish and fishery products offered for entry into the United States have been processed under conditions that comply with 21 CFR Part 123. If assurances do not exist that the imported fish or fishery product has been processed under conditions that are equivalent to those required of domestic processors under 21 CFR Part 123, the fish or fishery products will appear to be adulterated under Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4) and will be denied entry.\u003C\u002Fp>\u003Cp>Because our inspection identified serious violations for 21 CFR Part 123, your Tilapia imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Frozen Shrimp imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Frozen Shrimp Hoso imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> are adulterated under Section 402(a)(4) of the Act (21 U.S.C. § 342(a)(4)), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health.\u003C\u002Fp>\u003Cp>You may find the Act, the seafood HACCP regulation and the Fish and Fisheries Products Hazards &amp; Controls Guidance through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant violations were as follows as noted on the FDA 483 dated 01\u002F09\u002F2026:\u003C\u002Fp>\u003Cp>You do not have or have not implemented written verification procedures and an affirmative step for ensuring that fish and fishery products you import are processed in compliance with the Seafood HACCP regulation.\u003C\u002Fp>\u003Cp>This is a repeat observation from the previous inspection that concluded on 11\u002F17\u002F2022.\u003C\u002Fp>\u003Cp>Specifically, your written verification procedures (\"El Rey USA Meats &amp; Seafood Preventive Controls Plan\" and \"El Rey USA Meats &amp; Seafood Food Safety Plan Receive to Dispatch\") do not ensure that the following imported products were processed under conditions equivalent to U.S. HACCP requirements 21 CFR 123.12 (a) (2):\u003C\u002Fp>\u003Cp>Shrimp from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Shrimp from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Frozen Tilapia from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The documents lack written specifications designed to ensure that imported shrimp and tilapia are not adulterated under Section 402 of the Federal Food, Drug, and Cosmetic Act.\u003C\u002Fp>\u003Cp>Your written verification procedures do not identify which affirmation step(s) you have chosen to implement.\u003C\u002Fp>\u003Cp>The document \"El Rey USA Meats &amp; Seafood Food Safety Plan Receive to Dispatch\" was not signed and dated at the time of the activity, as required.\u003C\u002Fp>\u003Cp>This letter may not list all the violations at your facility. You are responsible for ensuring that your seafood importer establishment operates in compliance with the Act and the seafood HACCP regulation (21 CFR Part 123). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations for the fish or fishery products that you import into the United States.\u003C\u002Fp>\u003Cp>We acknowledge your response to these 483 violations, that was sent to us via email by Maria De La Luz, Operation Manager dated 01\u002F23\u002F2026. The response consisted of acknowledgment of the violations noted during our inspection that concluded on 01\u002F09\u002F2026 and a statement that you will be complying; however, this response has been deemed inadequate. On 01\u002F30\u002F2026, we provided Maria D. De la Luz, Operation Manager with an email explaining why this response was inadequate and as of the date of this letter, we have not received any additional information to address the inadequacies.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. You should include in your response documentation, such as HACCP and importer verification records and records that document the performance and results of your firm’s affirmative steps, or other useful information that would assist us in evaluating your corrections. If you cannot complete all corrections before you respond, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>We may take further action if you do not promptly correct these violations. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing your firm and the seafood products you import under \"Detention Without Physical Examination,\" seize your product(s) and\u002For enjoin your firm from further violating the Act.\u003C\u002Fp>\u003Cp>Please send your reply or if you have any questions regarding this letter via email to the Food and Drug Administration, Attention: Julie Scoma, Compliance Officer, julie.scoma@fda.hhs.gov, please reference CMS #722157 on any documents or records you provide and\u002For within the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Keith Jasukaitis\u003Cbr>Program Division Director\u003Cbr>300 River Place, Suite 5900\u003Cbr>Detroit, MI 48207-4291\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Daniel Leon Sr.\n\nRecipient Title\n\nCEO\n\nEl Rey USA Meats & Seafood Inc.\n\n2101 W. 74th St\n\nChicago, IL 60636-3652\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nFebruary 19, 2026\nWARNING LETTER\nRe: CMS# 722157\nDear Mr. Daniel Leon Sr.,\nWe inspected your seafood importer establishment, located at 2101 W. 74th St. Chicago, IL., 60636-3652 on January 5, 2026, through January 9, 2026. We conducted a previous inspection on November 15, 2022, through November 17, 2022, which resulted in your firm receiving a letter from FDA dated January 23, 2023, that explained your firm’s non-compliance with the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations Part 123 (21 CFR Part 123). This current follow-up inspection found that your firm still has serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). The specific requirements for imported fish and fishery products are set out in 21 CFR 123.12.\nAs an importer of fish or fishery products, you must operate in accordance with the requirements of Part 123. In accordance with 21 CFR 123.12(d), there must be evidence that all fish and fishery products offered for entry into the United States have been processed under conditions that comply with 21 CFR Part 123. If assurances do not exist that the imported fish or fishery product has been processed under conditions that are equivalent to those required of domestic processors under 21 CFR Part 123, the fish or fishery products will appear to be adulterated under Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4) and will be denied entry.\nBecause our inspection identified serious violations for 21 CFR Part 123, your Tilapia imported from (b)(4); Frozen Shrimp imported from (b)(4) and Frozen Shrimp Hoso imported from (b)(4) are adulterated under Section 402(a)(4) of the Act (21 U.S.C. § 342(a)(4)), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health.\nYou may find the Act, the seafood HACCP regulation and the Fish and Fisheries Products Hazards & Controls Guidance through links in FDA's home page at www.fda.gov.\nYour significant violations were as follows as noted on the FDA 483 dated 01\u002F09\u002F2026:\nYou do not have or have not implemented written verification procedures and an affirmative step for ensuring that fish and fishery products you import are processed in compliance with the Seafood HACCP regulation.\nThis is a repeat observation from the previous inspection that concluded on 11\u002F17\u002F2022.\nSpecifically, your written verification procedures (\"El Rey USA Meats & Seafood Preventive Controls Plan\" and \"El Rey USA Meats & Seafood Food Safety Plan Receive to Dispatch\") do not ensure that the following imported products were processed under conditions equivalent to U.S. HACCP requirements 21 CFR 123.12 (a) (2):\nShrimp from (b)(4)\nShrimp from (b)(4)\nFrozen Tilapia from (b)(4)\nThe documents lack written specifications designed to ensure that imported shrimp and tilapia are not adulterated under Section 402 of the Federal Food, Drug, and Cosmetic Act.\nYour written verification procedures do not identify which affirmation step(s) you have chosen to implement.\nThe document \"El Rey USA Meats & Seafood Food Safety Plan Receive to Dispatch\" was not signed and dated at the time of the activity, as required.\nThis letter may not list all the violations at your facility. You are responsible for ensuring that your seafood importer establishment operates in compliance with the Act and the seafood HACCP regulation (21 CFR Part 123). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations for the fish or fishery products that you import into the United States.\nWe acknowledge your response to these 483 violations, that was sent to us via email by Maria De La Luz, Operation Manager dated 01\u002F23\u002F2026. The response consisted of acknowledgment of the violations noted during our inspection that concluded on 01\u002F09\u002F2026 and a statement that you will be complying; however, this response has been deemed inadequate. On 01\u002F30\u002F2026, we provided Maria D. De la Luz, Operation Manager with an email explaining why this response was inadequate and as of the date of this letter, we have not received any additional information to address the inadequacies.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. You should include in your response documentation, such as HACCP and importer verification records and records that document the performance and results of your firm’s affirmative steps, or other useful information that would assist us in evaluating your corrections. If you cannot complete all corrections before you respond, you should explain the reason for your delay and state when you will correct any remaining violations.\nWe may take further action if you do not promptly correct these violations. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing your firm and the seafood products you import under \"Detention Without Physical Examination,\" seize your product(s) and\u002For enjoin your firm from further violating the Act.\nPlease send your reply or if you have any questions regarding this letter via email to the Food and Drug Administration, Attention: Julie Scoma, Compliance Officer, julie.scoma@fda.hhs.gov, please reference CMS #722157 on any documents or records you provide and\u002For within the subject line of the email.\nSincerely,\n\u002FS\u002F\nKeith Jasukaitis\nProgram Division Director\n300 River Place, Suite 5900\nDetroit, MI 48207-4291","El Rey USA Meats & Seafood Inc.","el-rey-usa-meats-seafood-inc-722157-02192026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fel-rey-usa-meats-seafood-inc-722157-02192026","2026-10-26T08:08:32.152615+00:00","2026-03-10","722157","Food & Beverages","Mr. Daniel Leon Sr.","2026-08-19T04:51:33.722+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2026-02-19",{"id":192,"raw":193,"subject":98,"body_html":199,"body_text":200,"firm_name":201,"letter_id":202,"created_at":203,"fei_number":19,"letter_url":204,"updated_at":205,"action_type":22,"case_status":206,"posted_date":207,"marcs_cms_no":208,"product_type":108,"closeout_date":209,"issuing_office":197,"recipient_name":210,"body_fetched_at":211,"delivery_method":212,"recipient_title":19,"reference_number":19,"action_taken_date":213,"medical_device_id":19,"response_letter_date":19},3526,[194,195,196,197,98,13,198,13],"\u003Ctime datetime=\"2021-02-19T17:00:00Z\">02\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-18T05:00:00Z\">02\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnative-remedies-dba-silver-star-brands-612268-02182021\">Native Remedies dba Silver Star Brands\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsilver-star-brands-inc-612268-09272021\">\u003Ctime datetime=\"2025-08-04T04:00:00Z\">08\u002F04\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bruce Valk\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Native Remedies dba Silver Star Brands\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>250 City Center\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oshkosh\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>54906\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>RE: [CMS:612268]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear \u003Cspan>Mr. Valk\u003C\u002Fspan>\u003Cspan>,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.nativeremedies.com\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>\u003Cspan>in\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>December 2020 and has determined that you take orders there for your \u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Drops and \u003C\u002Fspan>\u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Capsules\u003C\u002Fspan> products. The claims on your website establish that your \u003Cspan>products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>\u003Cspan>www.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>\u003Cspan>. &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>MindSoothe&nbsp;Drops\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Relieves feelings of depression\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Regulates disturbed sleep patterns (insomnia or&nbsp;hypersomnia)\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Improves disturbed appetite (loss of appetite or binge eating)\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>MindSoothe\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>™ should be taken when there is a noticeable loss of interest in activities that are normally enjoyable, a change in eating&nbsp;habits (such&nbsp;as overeating or appetite loss), or difficulty concentrating, remembering details, and making decisions.\"\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>MindSoothe&nbsp;Capsules\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Relieves feelings of depression\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Regulates disturbed sleep patterns (insomnia or&nbsp;hypersomnia)\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Improves disturbed appetite (loss of appetite or binge eating)\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"MindSoothe is ...formulated to relieve the symptoms of depression. ...without any of the&nbsp;harmful side effects possible with&nbsp;prescription medicine.\"&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Supporting emotional&nbsp;health... depression-free.\"&nbsp;[ellipsis in original]\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your\u003Cspan> website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of products for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"Your&nbsp;\u003C\u002Fspan>\u003Cb>\u003Ci>\u003Cspan>MindSoothe\u003C\u002Fspan>\u003C\u002Fi>\u003C\u002Fb>\u003Cspan>&nbsp;remedy&nbsp;helped my depression so much!\"\u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your \u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Drops and \u003C\u002Fspan>\u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Capsules\u003C\u002Fspan> products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. \u003Cspan>§§ \u003C\u002Fspan>331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. \u003Cspan>§ \u003C\u002Fspan>201.5).&nbsp; Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your \u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Drops and \u003C\u002Fspan>\u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Capsules\u003C\u002Fspan> products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your \u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Drops and \u003C\u002Fspan>\u003Cspan>MindSoothe\u003C\u002Fspan>\u003Cspan>&nbsp;Capsules\u003C\u002Fspan> products fail to bear adequate directions for their inte\u003Cspan>nded use and, therefore, these products are misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. \u003Cspan>§\u003C\u002Fspan> 331(a)]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>your firm complies with all requirements of federal law, including FDA\u003Cspan> regulations.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take prompt action to address the violations cited in this letter. &nbsp;Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.&nbsp; Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.&nbsp; If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fspan> \u003Cspan>Your reply should be sent via e-mail to \u003C\u002Fspan>\u003Ca href=\"mailto:FDAAdvisory@fda.hhs.gov\">\u003Cspan>FDAAdvisory@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>William A. Correll Jr.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nBruce Valk\n\nNative Remedies dba Silver Star Brands\n\n250 City Center\n\nOshkosh, WI 54906\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nRE: [CMS:612268]\n\nDear Mr. Valk,\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.nativeremedies.com in December 2020 and has determined that you take orders there for your MindSoothe Drops and MindSoothe Capsules products. The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nMindSoothe Drops\n\n\"Relieves feelings of depression\"\n\n\"Regulates disturbed sleep patterns (insomnia or hypersomnia)\"\n\n\"Improves disturbed appetite (loss of appetite or binge eating)\"\n\n\"MindSoothe™ should be taken when there is a noticeable loss of interest in activities that are normally enjoyable, a change in eating habits (such as overeating or appetite loss), or difficulty concentrating, remembering details, and making decisions.\"\n\nMindSoothe Capsules\n\n\"Relieves feelings of depression\"\n\n\"Regulates disturbed sleep patterns (insomnia or hypersomnia)\"\n\n\"Improves disturbed appetite (loss of appetite or binge eating)\"\n\n\"MindSoothe is ...formulated to relieve the symptoms of depression. ...without any of the harmful side effects possible with prescription medicine.\"\n\n\"Supporting emotional health... depression-free.\" [ellipsis in original]\n\nYour website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of products for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\n\"Your MindSoothe remedy helped my depression so much!\"\n\nYour MindSoothe Drops and MindSoothe Capsules products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour MindSoothe Drops and MindSoothe Capsules products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your MindSoothe Drops and MindSoothe Capsules products fail to bear adequate directions for their intended use and, therefore, these products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll Jr.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","Native Remedies dba Silver Star Brands","native-remedies-dba-silver-star-brands-612268-02182021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnative-remedies-dba-silver-star-brands-612268-02182021","2026-10-26T08:09:30.237291+00:00","Closed Out","2021-02-19","612268","2025-08-04","Bruce Valk","2026-08-20T03:22:19.077+00:00","Via Overnight Delivery","2021-02-18",{"id":215,"raw":216,"subject":221,"body_html":222,"body_text":223,"firm_name":224,"letter_id":225,"created_at":226,"fei_number":19,"letter_url":227,"updated_at":228,"action_type":22,"case_status":23,"posted_date":229,"marcs_cms_no":230,"product_type":26,"closeout_date":19,"issuing_office":220,"recipient_name":231,"body_fetched_at":232,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":233,"medical_device_id":19,"response_letter_date":19},2785,[217,218,219,220,221,13,13,13],"\u003Ctime datetime=\"2022-03-29T14:00:00Z\">03\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-28T04:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffunctional-remedies-llc-dba-synchronicity-hemp-oil-627208-03282022\">Functional Remedies, LLC D\u002FB\u002FA Synchronicity Hemp Oil\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew Campbell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Functional Remedies, LLC D\u002FB\u002FA Synchronicity Hemp Oil\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>331 S. 104th Street, Suite 210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Louisville\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80027\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@synchronicityhempoil.com\"> hello@synchronicityhempoil.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nRE: 627208\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 28, 2022\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fsynchronicityhempoil.com\u002F on February 16, 2022, and March 1, 2022, respectively. The FDA has observed that your website offers Full-Spectrum Hemp Oil and cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Hemp Oil has been shown to possibly reduce viral inflammation, known as a cytokines storm, which can be detrimental and even deadly to a person suffering from a viral infection, such as COVID-19.” [from a November 24, 2020 blog post titled “Can Hemp Oil Combat Inflammation and Viruses?” on your website https:\u002F\u002Fsynchronicityhempoil.com\u002Fhemp-oil-to-treat-inflammation-andviruses\u002F]\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>Exciting Discoveries: CBD and COVID-19\u003C\u002Fstrong> Research released in May 2020 revealed fascinating findings about the potential effects of cannabis on the COVID-19 virus: ‘Similar to other respiratory pathogens, SARS-CoV2 (COVID-19) is transmitted through respiratory droplets, with potential for aerosol and contact spread . . . ACE2 levels were in fact significantly down-regulated when specific strains of cannabis were introduced, supporting their theory that the anti-inflammatory properties of CBD could inhibit the virus’s ability to successfully bind to a host. Cannabinoids may decrease the number of receptors available to the virus giving your body more of a chance to fight it.” [from a November 24, 2020 blog post titled “Can Hemp Oil Combat Inflammation and Viruses?” on your website https:\u002F\u002Fsynchronicityhempoil.com\u002Fhemp-oil-to-treat-inflammation-and-viruses\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well- controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002Fs\u002F&nbsp;\u003Cbr>\nDonald D. Ashley&nbsp;\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance&nbsp;\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002Fs\u002F&nbsp;\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAndrew Campbell\n\nFunctional Remedies, LLC D\u002FB\u002FA Synchronicity Hemp Oil\n\n331 S. 104th Street, Suite 210\n\nLouisville, CO 80027\n\nUnited States\n\nhello@synchronicityhempoil.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 627208\n\nDate: March 28, 2022\n\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fsynchronicityhempoil.com\u002F on February 16, 2022, and March 1, 2022, respectively. The FDA has observed that your website offers Full-Spectrum Hemp Oil and cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Hemp Oil has been shown to possibly reduce viral inflammation, known as a cytokines storm, which can be detrimental and even deadly to a person suffering from a viral infection, such as COVID-19.” [from a November 24, 2020 blog post titled “Can Hemp Oil Combat Inflammation and Viruses?” on your website https:\u002F\u002Fsynchronicityhempoil.com\u002Fhemp-oil-to-treat-inflammation-andviruses\u002F]\n\n“Exciting Discoveries: CBD and COVID-19 Research released in May 2020 revealed fascinating findings about the potential effects of cannabis on the COVID-19 virus: ‘Similar to other respiratory pathogens, SARS-CoV2 (COVID-19) is transmitted through respiratory droplets, with potential for aerosol and contact spread . . . ACE2 levels were in fact significantly down-regulated when specific strains of cannabis were introduced, supporting their theory that the anti-inflammatory properties of CBD could inhibit the virus’s ability to successfully bind to a host. Cannabinoids may decrease the number of receptors available to the virus giving your body more of a chance to fight it.” [from a November 24, 2020 blog post titled “Can Hemp Oil Combat Inflammation and Viruses?” on your website https:\u002F\u002Fsynchronicityhempoil.com\u002Fhemp-oil-to-treat-inflammation-and-viruses\u002F]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well- controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002Fs\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002Fs\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n_______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Functional Remedies, LLC D\u002FB\u002FA Synchronicity Hemp Oil","functional-remedies-llc-dba-synchronicity-hemp-oil-627208-03282022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffunctional-remedies-llc-dba-synchronicity-hemp-oil-627208-03282022","2026-10-26T08:08:44.097548+00:00","2022-03-29","627208","Andrew Campbell","2026-08-20T02:04:12.236+00:00","2022-03-28",11,{"510k":236,"classification":237,"enforcement":238,"event":239,"event_backfill":240,"pma":241,"warning_letter":242},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]